[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Wipro GE Healthcare Private Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":209},{"warningLetters":4,"total":208},[5,32,54,74,94,113,136,152,169,190],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},18,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-13T04:00:00Z\">07\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falmon-healthcare-private-limited-729291-07132026\">Almon Healthcare Private Limited\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-102\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Rajesh Gandhi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Almon Healthcare Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382240\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-102\u003C\u002Fp>\u003Cp>July 13, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Gandhi:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Almon Healthcare Private Limited, FEI 3030509366, at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, from February 9 to 13, 2026.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 6, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure of your quality unit to exercise its responsibility to ensure the API and intermediates manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to perform identity testing on incoming raw materials used in the manufacture of APIs \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which are intended for use in pharmacy compounding.\u003C\u002Fp>\u003Cp>Specifically, your firm intentionally accepted lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were deliberately mislabeled by your supplier as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, your QU admitted that this was a deliberate and ongoing practice since 2024 to circumvent your firm’s lack of a required \u003Cstrong>(b)(4)\u003C\u002Fstrong> license. You subsequently used this mislabeled and untested material to manufacture multiple batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that you ultimately shipped to the United States. Furthermore, your QU relied on your supplier’s certificate of analysis without conducting supplier qualification as your standard operating procedure requires.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the mislabeling practice, state you have since obtained the required \u003Cstrong>(b)(4)\u003C\u002Fstrong> license, and commit to performing identity testing of all future lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also state that a retrospective reevaluation of residual solvent chromatographic data confirms that peaks previously observed in the affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches are attributable to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your analytical conclusions are unsubstantiated because your response does not provide the supporting chromatograms or results from your identity tests. Furthermore, you do not provide a risk assessment for batches already distributed to the United States. Your response also does not address the systemic quality failure that allowed your firm to knowingly accept and recode mislabeled materials without performing identity testing. Finally, you fail to propose any substantive corrective actions to remediate your supplier qualification program to prevent a recurrence of this critical failure.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>Your practice of receiving \u003Cstrong>(b)(4)\u003C\u002Fstrong> mislabeled as \u003Cstrong>(b)(4)\u003C\u002Fstrong> poses a significant safety risk to personnel who may handle the material without knowing its true identity. Due to lack of awareness, workers may fail to take the precautions necessary to prevent exposure. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is acutely toxic to humans and has caused fatal poisoning incidents worldwide.\u003C\u002Fp>\u003Cp>Furthermore, an adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP, including the sections on quality oversight. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also describe how top management supports quality assurance and reliable operations including, but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to ensure that all test procedures are scientifically sound and appropriate to ensure that your intermediate and API conform to established standards of quality and purity.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to validate or adequately verify multiple test methods used for testing key starting materials and finished APIs. Specifically, you did not validate the in-house analytical methods, including the stability-indicating methods, used to support the \u003Cstrong>(b)(4)\u003C\u002Fstrong> retest dates for your products shipped to the United States. Furthermore, your firm failed to adequately implement and verify an analytical method transferred from your contract testing laboratory CTL) used for routine testing and stability studies of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your implemented method was unable to detect multiple unknown impurities that your CTL’s validated method identified.\u003C\u002Fp>\u003Cp>In your response, you commit to executing forced degradation studies to demonstrate your methods are stability-indicating and to reassessing the validity of the assigned \u003Cstrong>(b)(4)\u003C\u002Fstrong> retest dates for the APIs shipped to the United States. You also commit to executing validation and verification protocols for compendial and in-house methods. You attribute the discrepancy in impurity detection in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to an incorrectly set processing threshold and provide reprocessed data to suggest your results are now comparable.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to comprehensively assess your laboratory systems to ensure that all test methods are appropriately validated or verified. You have not established any interim controls for ongoing production while you conduct your retrospective review of batches tested with unvalidated methods. Additionally, while you attempt to explain the threshold differences between the CTL and the in-house verification study for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you fail to address whether the methods are truly equivalent.\u003C\u002Fp>\u003Cp>Without an appropriate laboratory and stability-indicating methods, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of validated\u002Fverified chemical specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive assessment and corrective action and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability-indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program\u003C\u002Fli>\u003Cli>Confirm the retest dates for \u003Cstrong>(b)(4)\u003C\u002Fstrong> using the revalidated stability-indicating method. This reassessment should ensure that all previously assigned retest dates are accurate.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Failure to clean equipment to prevent contamination or carry-over of a material that would alter the quality of the intermediates and API beyond the official or other established specifications.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately clean and maintain non-dedicated API manufacturing equipment used to manufacture as many as \u003Cstrong>(b)(4)\u003C\u002Fstrong> different APIs. For example, our investigator observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles on product contact surfaces, including the lid and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid draining from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> even though the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was documented as “empty and cleaned.” Additionally, your firm failed to maintain cleaning records for a non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> product transfer pipe.\u003C\u002Fp>\u003Cp>Your cleaning verification report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> addressed only batch-to-batch cleaning. It did not address product changeover. It also lacked scientific justification for product selection and residue limit calculations based on solubility, difficulty of cleaning, and toxicity, as required by your cleaning validation procedure. Your firm affirmed to our investigator that no formal cleaning validation has been performed and that you have not established a maximum allowable carryover limit as required by your procedure.\u003C\u002Fp>\u003Cp>In your response, you attribute the observed residues on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the previous batch of the same non-U.S. API, explaining that only a “gross cleaning” is performed between batches during a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You conclude there was no risk of carryover. You assert that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> transfer pipe is dedicated to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and also conclude there is no cross-contamination risk and confirm you do not use cleaning logs.\u003C\u002Fp>\u003Cp>Furthermore, you state that you “executed cleaning validation\u002Fverification activities for selected products” manufactured on shared equipment.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not provide assurance that your cleaning processes are adequate to prevent cross-contamination and carryover risks. It addresses only the \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles observed in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, attributing them to a non-U.S. API campaign, while failing to test the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid and other particle deposits. You did not expand your investigation to other equipment or conduct a retrospective review of released batches to assess product impact.\u003C\u002Fp>\u003Cp>Your claim that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> transfer pipe is dedicated to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> is unsubstantiated and contradicts information provided during the inspection. Further, you do not explain why cleaning validation was limited to selected products, nor do you provide supporting documentation to support or demonstrate that your cleaning practices adequately remove product residues.\u003C\u002Fp>\u003Cp>Inadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API’s quality and safety.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment of whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture intermediates and API products.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your API manufacturing operations. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher potencies\u003Cbr>o Drugs with lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003Cli>A summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on June 9, 2026.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Almon Healthcare Private Limited located at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3030509366 and ATTN: Jamie Dion.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-102\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Rajesh Gandhi\n\nRecipient Title\n\nChairman\n\nAlmon Healthcare Private Limited\n\nPlot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala\n\nAhmedabad 382240\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-102\nJuly 13, 2026\nDear Mr. Gandhi:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Almon Healthcare Private Limited, FEI 3030509366, at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, from February 9 to 13, 2026.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 6, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific deviations including, but not limited to, the following.\n1. Failure of your quality unit to exercise its responsibility to ensure the API and intermediates manufactured at your facility are in compliance with CGMP.\nYour quality unit (QU) failed to perform identity testing on incoming raw materials used in the manufacture of APIs (b)(4), which are intended for use in pharmacy compounding.\nSpecifically, your firm intentionally accepted lots of (b)(4) that were deliberately mislabeled by your supplier as (b)(4). During the inspection, your QU admitted that this was a deliberate and ongoing practice since 2024 to circumvent your firm’s lack of a required (b)(4) license. You subsequently used this mislabeled and untested material to manufacture multiple batches of (b)(4) that you ultimately shipped to the United States. Furthermore, your QU relied on your supplier’s certificate of analysis without conducting supplier qualification as your standard operating procedure requires.\nIn your response, you acknowledge the mislabeling practice, state you have since obtained the required (b)(4) license, and commit to performing identity testing of all future lots of (b)(4). You also state that a retrospective reevaluation of residual solvent chromatographic data confirms that peaks previously observed in the affected (b)(4) batches are attributable to (b)(4).\nYour response is inadequate. Your analytical conclusions are unsubstantiated because your response does not provide the supporting chromatograms or results from your identity tests. Furthermore, you do not provide a risk assessment for batches already distributed to the United States. Your response also does not address the systemic quality failure that allowed your firm to knowingly accept and recode mislabeled materials without performing identity testing. Finally, you fail to propose any substantive corrective actions to remediate your supplier qualification program to prevent a recurrence of this critical failure.\nWithout adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nYour practice of receiving (b)(4) mislabeled as (b)(4) poses a significant safety risk to personnel who may handle the material without knowing its true identity. Due to lack of awareness, workers may fail to take the precautions necessary to prevent exposure. (b)(4) is acutely toxic to humans and has caused fatal poisoning incidents worldwide.\nFurthermore, an adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP, including the sections on quality oversight. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no Also describe how top management supports quality assurance and reliable operations including, but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n2. Failure to ensure that all test procedures are scientifically sound and appropriate to ensure that your intermediate and API conform to established standards of quality and purity.\nYour firm failed to validate or adequately verify multiple test methods used for testing key starting materials and finished APIs. Specifically, you did not validate the in-house analytical methods, including the stability-indicating methods, used to support the (b)(4) retest dates for your products shipped to the United States. Furthermore, your firm failed to adequately implement and verify an analytical method transferred from your contract testing laboratory CTL) used for routine testing and stability studies of (b)(4). Your implemented method was unable to detect multiple unknown impurities that your CTL’s validated method identified.\nIn your response, you commit to executing forced degradation studies to demonstrate your methods are stability-indicating and to reassessing the validity of the assigned (b)(4) retest dates for the APIs shipped to the United States. You also commit to executing validation and verification protocols for compendial and in-house methods. You attribute the discrepancy in impurity detection in (b)(4) to an incorrectly set processing threshold and provide reprocessed data to suggest your results are now comparable.\nYour response is inadequate because it fails to comprehensively assess your laboratory systems to ensure that all test methods are appropriately validated or verified. You have not established any interim controls for ongoing production while you conduct your retrospective review of batches tested with unvalidated methods. Additionally, while you attempt to explain the threshold differences between the CTL and the in-house verification study for (b)(4), you fail to address whether the methods are truly equivalent.\nWithout an appropriate laboratory and stability-indicating methods, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of validated\u002Fverified chemical specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive assessment and corrective action and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability-indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program\nConfirm the retest dates for (b)(4) using the revalidated stability-indicating method. This reassessment should ensure that all previously assigned retest dates are accurate.\n3. Failure to clean equipment to prevent contamination or carry-over of a material that would alter the quality of the intermediates and API beyond the official or other established specifications.\nYour firm failed to adequately clean and maintain non-dedicated API manufacturing equipment used to manufacture as many as (b)(4) different APIs. For example, our investigator observed (b)(4) and (b)(4) particles on product contact surfaces, including the lid and (b)(4) of (b)(4), and (b)(4) liquid draining from the (b)(4) even though the (b)(4) was documented as “empty and cleaned.” Additionally, your firm failed to maintain cleaning records for a non-dedicated (b)(4) product transfer pipe.\nYour cleaning verification report for (b)(4) addressed only batch-to-batch cleaning. It did not address product changeover. It also lacked scientific justification for product selection and residue limit calculations based on solubility, difficulty of cleaning, and toxicity, as required by your cleaning validation procedure. Your firm affirmed to our investigator that no formal cleaning validation has been performed and that you have not established a maximum allowable carryover limit as required by your procedure.\nIn your response, you attribute the observed residues on the (b)(4) to the previous batch of the same non-U.S. API, explaining that only a “gross cleaning” is performed between batches during a (b)(4). You conclude there was no risk of carryover. You assert that the (b)(4) transfer pipe is dedicated to a (b)(4) and also conclude there is no cross-contamination risk and confirm you do not use cleaning logs.\nFurthermore, you state that you “executed cleaning validation\u002Fverification activities for selected products” manufactured on shared equipment.\nYour response is inadequate because it does not provide assurance that your cleaning processes are adequate to prevent cross-contamination and carryover risks. It addresses only the (b)(4) particles observed in the (b)(4), attributing them to a non-U.S. API campaign, while failing to test the observed (b)(4) liquid and other particle deposits. You did not expand your investigation to other equipment or conduct a retrospective review of released batches to assess product impact.\nYour claim that the (b)(4) transfer pipe is dedicated to a (b)(4) is unsubstantiated and contradicts information provided during the inspection. Further, you do not explain why cleaning validation was limited to selected products, nor do you provide supporting documentation to support or demonstrate that your cleaning practices adequately remove product residues.\nInadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API’s quality and safety.\nIn response to this letter, provide:\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment of whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture intermediates and API products.\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your API manufacturing operations. This should include but not be limited to identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher potencies\no Drugs with lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nA summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nCGMP Consultant Recommended\nBased upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on June 9, 2026.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Almon Healthcare Private Limited located at Plot No 4, Sankalp Industrial Estate, Behind Kerala GIDC, Bavala, Ahmedabad, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3030509366 and ATTN: Jamie Dion.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Almon Healthcare Private Limited","almon-healthcare-private-limited-729291-07132026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falmon-healthcare-private-limited-729291-07132026","2026-10-26T08:07:52.860413+00:00","Warning Letter","Issued","2026-07-21","729291","Drugs","Mr. Rajesh Gandhi","2026-08-19T04:28:21.954+00:00","Via Email Return Receipt Requested","320-26-102","2026-07-13",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":52,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},821,[35,36,37,11,38,13,13,13],"\u003Ctime datetime=\"2025-06-17T04:00:00Z\">06\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-12T04:00:00Z\">06\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkenil-healthcare-private-limited-704786-06122025\">Kenil Healthcare Private Limited\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-81\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Anil Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kenil Healthcare Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 319, Village Acharasan, Ankhol-Vamaj Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tal-Kadi, District Mehsana\u003C\u002Fspan> \u003Cspan>382715\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-81\u003C\u002Fp>\u003Cp>June 12, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kenil Healthcare Private Limited, FEI 3022380309, at Plot No. 319, Village Acharasan, Ankhol-Vamaj Road, Tal-Kadi, District Mehsana, Gujarat, from December 5 to 11, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your December 30, 2024 response and subsequent correspondences to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately clean and maintain your filling rooms and tube filling equipment used to manufacture your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> over-the-counter (OTC) drug products. For example, our investigators observed the following:\u003C\u002Fp>\u003Cul>\u003Cli>The presence of mold and dirt on the walls in your filling and sealing rooms.\u003C\u002Fli>\u003Cli>Soiled and stained air handling units.\u003C\u002Fli>\u003Cli>Unidentified product buildup inside your \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing vessel and tube filling equipment.\u003C\u002Fli>\u003Cli>More than one drug product was found on the packaging line.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, your firm did not have validated cleaning procedures, including written equipment usage and cleaning logs to demonstrate that your drug product manufacturing equipment was adequately cleaned and maintained.\u003C\u002Fp>\u003Cp>In your response, you state that you revised your cleaning procedures and logbooks and commit to retrain your staff on cleaning practices and procedures. You also state that cleaning and sanitization of the filling and sealing rooms was conducted and building maintenance will be performed. Your response is inadequate because you failed to provide supporting data to demonstrate that your cleaning practices are sufficient to remove contaminants from the product surfaces of your drug product manufacturing equipment. You also failed to provide any documentation that the above-mentioned activities occurred. Furthermore, you failed to assess the impact of your inadequate cleaning processes on products that are currently on the market and within expiry.\u003C\u002Fp>\u003Cp>It is essential that your facility and equipment are cleaned, and sanitary conditions are maintained, to ensure ongoing suitability for drug manufacturing, and to protect drug products from contamination.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>Additional photographic evidence that demonstrates thorough cleaning of your filling and sealing areas, including but not limited to Rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the completion of all necessary building maintenance in those areas.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products with adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination (21 CFR 211.42(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s packaging and labeling operations are performed without adequate controls to prevent mix-ups and cross-contamination. For example, our investigators observed employees performing manual packaging and labeling operations on the floor of the manufacturing room. Investigators also noted that multiple drug products were packaged simultaneously without adequate separation and spacing. The drug products were also packaged without the use of batch records.\u003C\u002Fp>\u003Cp>Our investigators also observed that your reserve samples were improperly stored, commingled with expired products, and lacked routine monitoring.\u003C\u002Fp>\u003Cp>In your response, you state that you implemented procedures for dispensing and issuing packaging materials. Your response also includes plans to expand your warehouse. Your response is inadequate because you failed to address the interim plans to prevent labeling mixups in your current packaging area while you remediate your lack of adequate facility spacing. You also do not describe how you intend to ensure that the procedural updates are effective.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan to improve packaging and labeling operations, including equipment and facility upgrades, effective preventive and corrective maintenance, enhanced performance monitoring, improved operations management oversight, and any other needed actions. Your CAPA plan should also assure the proper segregation and sufficient space for the orderly storage of samples.\u003C\u002Fli>\u003Cli>An action plan and timeline for conducting retrospective assessment of all your reserve samples in your sample storage area. Include supporting documentation to ensure that no product or package mix-ups have occurred, and any corrective actions, such as notifying customers of identified product mix-ups.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Review and approval of written procedures for production and process controls that are designed to assure the quality of your drug products, i.e., process validation (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Adequate batch production and control records that include complete documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\u003C\u002Fli>\u003Cli>Adequate review and approval of production and control records before a batch is released or distributed (21 CFR 211.192)\u003C\u002Fli>\u003Cli>Production and process control activities, such as equipment qualification, are documented at the time of performance (21 CFR 211.100(b)). Specifically, investigators observed your quality assurance manager generating and completing equipment qualification documents investigators previously requested. This practice raises concerns about the integrity and reliability of your firm’s data and documentation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at \u003Cem>Data Integrity and Compliance With Drug CGMP:\u003C\u002Fem>\u003Cbr>\u003Cem>Questions and Answers | FDA\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan.\u003C\u002Fli>\u003Cli>Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate, including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of your data integrity lapses, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding batches to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On March 26, 2025, FDA held a teleconference with you and your U.S. Agent, JMM Services LLC. We recommended that you recall all your drug products within expiry currently in distribution to the U.S. market. On April 9, 2025, your firm committed to recall the products within expiry. After several subsequent attempts were made to contact you and your registered U.S. Agent regarding the recall, you initiated the recall of all your drug products on April 24, 2025.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&amp;C Act (21 U.S.C. 361(c)) if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health. Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 4, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Kenil Healthcare Private Limited, located at Plot No. 319, Village Acharasan, Ankhol-Vamaj Road Ta-Kadi, District Mehsana, Gujarat, 382715, India, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3022380309 and ATTN: Yvette Johnson.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: Registered U.S. Agent\u003Cbr>Ms. Julia Moffitt, JMM Services\u003Cbr>Email: julia@jmm.one; Info@jmm.one\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-81\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Anil Patel\n\nRecipient Title\n\nOwner and Director\n\nKenil Healthcare Private Limited\n\nPlot No. 319, Village Acharasan, Ankhol-Vamaj Road\n\nTal-Kadi, District Mehsana 382715\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-81\nJune 12, 2025\nDear Mr. Patel:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kenil Healthcare Private Limited, FEI 3022380309, at Plot No. 319, Village Acharasan, Ankhol-Vamaj Road, Tal-Kadi, District Mehsana, Gujarat, from December 5 to 11, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your December 30, 2024 response and subsequent correspondences to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\nYou failed to adequately clean and maintain your filling rooms and tube filling equipment used to manufacture your (b)(4) and (b)(4) over-the-counter (OTC) drug products. For example, our investigators observed the following:\nThe presence of mold and dirt on the walls in your filling and sealing rooms.\nSoiled and stained air handling units.\nUnidentified product buildup inside your (b)(4) manufacturing vessel and tube filling equipment.\nMore than one drug product was found on the packaging line.\nIn addition, your firm did not have validated cleaning procedures, including written equipment usage and cleaning logs to demonstrate that your drug product manufacturing equipment was adequately cleaned and maintained.\nIn your response, you state that you revised your cleaning procedures and logbooks and commit to retrain your staff on cleaning practices and procedures. You also state that cleaning and sanitization of the filling and sealing rooms was conducted and building maintenance will be performed. Your response is inadequate because you failed to provide supporting data to demonstrate that your cleaning practices are sufficient to remove contaminants from the product surfaces of your drug product manufacturing equipment. You also failed to provide any documentation that the above-mentioned activities occurred. Furthermore, you failed to assess the impact of your inadequate cleaning processes on products that are currently on the market and within expiry.\nIt is essential that your facility and equipment are cleaned, and sanitary conditions are maintained, to ensure ongoing suitability for drug manufacturing, and to protect drug products from contamination.\nIn response to this letter, provide:\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nAdditional photographic evidence that demonstrates thorough cleaning of your filling and sealing areas, including but not limited to Rooms (b)(4) and (b)(4), and the completion of all necessary building maintenance in those areas.\n2. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products with adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination (21 CFR 211.42(b)).\nYour firm’s packaging and labeling operations are performed without adequate controls to prevent mix-ups and cross-contamination. For example, our investigators observed employees performing manual packaging and labeling operations on the floor of the manufacturing room. Investigators also noted that multiple drug products were packaged simultaneously without adequate separation and spacing. The drug products were also packaged without the use of batch records.\nOur investigators also observed that your reserve samples were improperly stored, commingled with expired products, and lacked routine monitoring.\nIn your response, you state that you implemented procedures for dispensing and issuing packaging materials. Your response also includes plans to expand your warehouse. Your response is inadequate because you failed to address the interim plans to prevent labeling mixups in your current packaging area while you remediate your lack of adequate facility spacing. You also do not describe how you intend to ensure that the procedural updates are effective.\nIn response to this letter, provide:\nYour CAPA plan to improve packaging and labeling operations, including equipment and facility upgrades, effective preventive and corrective maintenance, enhanced performance monitoring, improved operations management oversight, and any other needed actions. Your CAPA plan should also assure the proper segregation and sufficient space for the orderly storage of samples.\nAn action plan and timeline for conducting retrospective assessment of all your reserve samples in your sample storage area. Include supporting documentation to ensure that no product or package mix-ups have occurred, and any corrective actions, such as notifying customers of identified product mix-ups.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\nReview and approval of written procedures for production and process controls that are designed to assure the quality of your drug products, i.e., process validation (21 CFR 211.100(a)).\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\nAdequate batch production and control records that include complete documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\nAdequate review and approval of production and control records before a batch is released or distributed (21 CFR 211.192)\nProduction and process control activities, such as equipment qualification, are documented at the time of performance (21 CFR 211.100(b)). Specifically, investigators observed your quality assurance manager generating and completing equipment qualification documents investigators previously requested. This practice raises concerns about the integrity and reliability of your firm’s data and documentation.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at Data Integrity and Compliance With Drug CGMP:\nQuestions and Answers | FDA\nWe acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements.\nIn response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global CAPA plan.\nYour strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate, including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of your data integrity lapses, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding batches to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nDrug Recall\nOn March 26, 2025, FDA held a teleconference with you and your U.S. Agent, JMM Services LLC. We recommended that you recall all your drug products within expiry currently in distribution to the U.S. market. On April 9, 2025, your firm committed to recall the products within expiry. After several subsequent attempts were made to contact you and your registered U.S. Agent regarding the recall, you initiated the recall of all your drug products on April 24, 2025.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&C Act (21 U.S.C. 361(c)) if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health. Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 4, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Kenil Healthcare Private Limited, located at Plot No. 319, Village Acharasan, Ankhol-Vamaj Road Ta-Kadi, District Mehsana, Gujarat, 382715, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3022380309 and ATTN: Yvette Johnson.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCc: Registered U.S. Agent\nMs. Julia Moffitt, JMM Services\nEmail: julia@jmm.one; Info@jmm.one","Kenil Healthcare Private Limited","kenil-healthcare-private-limited-704786-06122025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkenil-healthcare-private-limited-704786-06122025","2026-10-26T08:09:08.479043+00:00","2025-06-17","704786","Mr. Anil Patel","2026-08-19T16:39:44.873+00:00","VIA Electronic Mail","320-25-81","2025-06-12",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":26,"closeout_date":19,"issuing_office":60,"recipient_name":71,"body_fetched_at":72,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},1748,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2023-11-14T14:20:00Z\">11\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-20T04:00:00Z\">10\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-pharma-healthcare-private-limited-657325-10202023\">Global Pharma Healthcare Private Limited\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. A.R. Venkatesh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Pharma Healthcare Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>A-9 SIDCO Pharmaceutical Complex\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thiruporur\u003C\u002Fspan> \u003Cspan>603110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-24-03\u003C\u002Fp>\n\n\u003Cp>October 20, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Venkatesh:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Global Pharma Healthcare Private Limited, FEI 3012323885, at A-9 SIDCO Pharmaceutical Complex, Thiruporur, from February 20 to March 2, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Because your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(A)\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>In addition, EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), and Delsam Pharma’s ARTIFICIAL EYE OINTMENT is further misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>\u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> Outbreak and FDA Testing of Samples\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In December 2022, FDA began collaborating with the Center for Disease Control and Prevention (CDC) on an investigation into the multistate outbreak of antibiotic-resistant \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> infections that ultimately affected more than 80 patients and led to 4 patient deaths and at least 14 cases of vision loss. As part of this investigation, FDA collected finished product samples of Artificial Tears and Artificial Eye Ointment batches that were manufactured by your facility, and we sent the samples for sterility testing at FDA laboratories. Our analysis of intact (unopened) units found that 18 batches of Artificial Tears were non-sterile. In addition, we also sampled a batch of your Artificial Eye Ointment product, and this batch was also found to be non-sterile. The testing of these intact units revealed that your ophthalmic drug products were intrinsically contaminated with microorganisms. Microbiological isolates from the non-sterile samples were further characterized using whole genome sequencing and compared to isolates in a national database.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> isolates from three different batches of intact Artificial Tears samples collected by FDA were found to be close genetic matches to more than 85 clinical isolates associated with this outbreak. These test results demonstrate that these lots are adulterated under section 501(a)(1) of the FD&amp;C Act, in that they have been contaminated with filth, and rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>Significantly, the pervasive contamination of your drug products, as indicated by FDA sample results, also demonstrates that all drugs made at your facility are adulterated under section 501(a)(2)(A) of the FD&amp;C Act as they have been manufactured under insanitary conditions.\u003C\u002Fp>\n\n\u003Cp>In addition, two intact samples of Artificial Tears from different batches were found to contain visible, foreign particles.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 22, 2023, response to our Form FDA 483 in detail. During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Equipment and Processes\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>A. You lacked adequate scientific evidence that the aseptic filling machine used for manufacture of Artificial Tears was suitable for its intended use. Your qualification report was inadequate, including a lack of data on any batches filled as part of the qualification study. Further, all batches of Artificial Tears distributed to the U.S. market were manufactured using filling machine parameters that were outside the design specifications of the equipment.\u003C\u002Fp>\n\n\u003Cp>B. You lacked validation of the processes used to manufacture your aseptically filled Artificial Tears, for example:\u003C\u002Fp>\n\n\u003Cp>• You failed to validate methods that were intended to render your ophthalmic drug products sterile. Specifically, you lacked a study to show the \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed on your Artificial Tears product using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> can reliably achieve sterilization.\u003C\u002Fp>\n\n\u003Cp>• Your media fill program lacked assurance that aseptic processing operations are appropriately performed to prevent microbial contamination. Our inspection found that you failed to perform appropriate and sufficient media fills studies, for example:\u003Cbr>\n&nbsp; &nbsp; o Your media fills failed to adequately simulate the commercial aseptic manufacturing operation. Interventions were not simulated sufficiently or accurately. In addition, you have a manually intensive line with minimal barrier protection where the possibility of contamination is greater. Despite this, you filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>-\u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the production batch size during media fills.\u003Cbr>\n&nbsp; &nbsp; o Manufacturing lines used to produce the Artificial Tears and Artificial Eye Ointment products were not qualified by three successful media fills.\u003Cbr>\n&nbsp; &nbsp; o You removed integral units (i.e., units with intact container-closure systems) from media fills without adequate justification and failed to incubate all integral units for the full \u003Cstrong>(b)(4)\u003C\u002Fstrong> period.\u003Cbr>\n&nbsp; &nbsp; o The personnel responsible for visual inspection of media-filled units lacked appropriate training and qualification.\u003C\u002Fp>\n\n\u003Cp>C. You lacked meaningful airflow pattern studies for your aseptic processing lines. The studies were not performed under dynamic conditions and lacked simulation of interventions and other routine activities that occur during aseptic manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>D. Your firm also shipped an ointment product to the United States that was manufactured using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process. You failed to ensure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process employed by your contractor to sterilize your Artificial Eye Ointment was validated.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate, including the following:\u003C\u002Fp>\n\n\u003Cp>• You lack details of your internal investigation into the product contamination. Your investigation is not comprehensive, including but not limited to, a lack of descriptions of the activities performed and root cause analysis. You also lack details on sampling and laboratory methods used for environmental and other tests.\u003C\u002Fp>\n\n\u003Cp>• There is a lack of detail relating to future dynamic airflow pattern studies; heating, ventilation, and air conditioning (HVAC) system qualification; or media fill procedural revisions.\u003C\u002Fp>\n\n\u003Cp>• You also fail to include a commitment to validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process and sterility test methods for the Artificial Eye Ointment products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Container Closure Integrity\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You lacked evidence of reliable container closure integrity for your multi-use ophthalmic products that purport to be sterile. While visual inspections revealed leakers during batch manufacture, there was no assurance that your visual inspection procedure was adequate.\u003C\u002Fp>\n\n\u003Cp>Your product distributors received complaints of leaking Artificial Tears and Artificial Eye Ointment units. FDA’s laboratory performed container closure integrity testing of Artificial Eye Ointment, batch H29, manufactured at your facility. FDA tested 20 units, and 1 unit was found to allow microbiological ingress, which further confirmed that your container-closure system lacks integrity and is insufficient for maintaining sterility. Notably, batch H29 was also found to be non-sterile through FDA testing.\u003C\u002Fp>\n\n\u003Cp>All sterile drugs must be packaged using a container-closure system that protects product integrity for the duration of its shelf-life. Maintenance of product integrity throughout stresses of its manufacture, storage, distribution, and consumer use is critical to product quality and safety. Loss of container-closure integrity is a direct cause of non-sterility of medicines.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will perform container-closure integrity testing using a dye ingress method for your Artificial Tears product and a comprehensive sterility assessment. Your response is inadequate because your container-closure integrity testing protocol does not extend to Artificial Eye Ointment. In addition, you do not sufficiently address the sensitivity of your dye ingress method. The sensitivity of the method to be employed for your study is unclear, and you do not indicate whether it is capable of correlating with detection of bacteria comparable in size to\u003Cem> Pseudomonas aeruginosa\u003C\u002Fem>. Furthermore, your response does not include details on the comprehensive sterility assessment.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Formulation for Artificial Tears and Artificial Eye Ointment\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You manufactured multi-dose, over-the-counter (OTC) ophthalmic drug products for the product owners, EzriCare LLC, and Delsam Pharma LLC. These products lacked antimicrobial properties to preserve the formulation. Significantly, your firm also marketed this multi-dose product without performing antimicrobial effectiveness studies. It is essential that multi-dose ophthalmic drug products contain one or more suitable substances that will preserve the product and minimize the hazard of injury resulting from incidental contamination during use.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that antimicrobial effectiveness testing (AET) will be initiated for your Artificial Tears product, and you will use these studies to determine if a suitable preservative will be added to the formulation. Your response is inadequate because you do not explain why you failed to perform AET studies prior to launch of your drug product, and how you will correct such fundamental flaws in your product development program. You also make no commitment to conduct AET for the Artificial Eye Ointment formulation. In addition, although your protocol indicates that you follow the United States Pharmacopeia (USP), the acceptance criteria in the Artificial Tears protocol is less stringent and not in alignment with USP &lt;51&gt; \u003Cem>Antimicrobial Effectiveness Testing\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Gowning Practices &amp; Operator Qualification\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Cleanroom operators lacked adequate gowning and qualification for performing aseptic operations. Your deficient practices and procedures placed products at high risk for contamination, for example:\u003C\u002Fp>\n\n\u003Cp>A. A gowning demonstration revealed that cleanroom operators do not don sterile goggles and therefore have exposed skin around their eyes during aseptic operations.\u003C\u002Fp>\n\n\u003Cp>B. Cleanroom garments were not suitable for their intended use. For example, garments indicated to be clean were observed to be stained, worn out, and stored improperly. In addition, your firm re-used cleanroom garments for an unspecified number of times without tracking or validation.\u003C\u002Fp>\n\n\u003Cp>C. You lacked written procedures and a training program on proper aseptic behavior and gowning for cleanroom operators. You also lacked evidence that all cleanroom operators are qualified through participation in a media fill, and the microbiological limit set in your gowning validation procedure is unsuitable for aseptic operations.\u003C\u002Fp>\n\n\u003Cp>D. You lacked written procedures and a training program on proper aseptic behavior and gowning for cleanroom operators. You also lacked evidence that all cleanroom operators were qualified through participation in a media fill and justification for the microbiological limits used in your aseptic processing operator gowning qualification procedure (i.e., no more than (NMT) \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (cfu) for each gowning location). You also lacked a commitment to systematically review staff qualifications and competencies throughout your operation, including but not limited to, ensuring an effective CGMP training program.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that gowning qualification will be performed through media fills, and an in-house study will evaluate the impact of repeated sterilization cycles on cleanroom garments to establish an acceptable number of sterilization cycles. Your response is inadequate. You lack a comprehensive review of all aspects of personnel gowning, the qualification program, aseptic technique, cleanroom behavior, and an examination of the role of people as a contamination hazard in your processes. To further illustrate, you continue to lack substantive actions to implement sterile goggles, enhance practices to prevent sterile gown contamination, gowning qualification criteria (e.g., sampling requirements, location descriptions, acceptance limits with justifications), and many other basic elements of a compliant sterile facility. Your response also fails to address how your inadequate gowning practices impacted your sterile drug products.\u003Cbr>\nSee FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>\n&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cp>• A detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility. Explain how your corrective action and preventive action (CAPA) will robustly remediate your deficient sterile manufacturing operation. Also describe your plans for qualification and validation of your comprehensively remediated facility, processes and equipment.\u003C\u002Fp>\n\n\u003Cp>• A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>• Your plan to ensure that inspection and other quality control methods for container-closure systems, including but not limited to opaque bottles and ointment tubes, can robustly detect integrity breaches.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of the qualifications and competencies of staff to conduct their job duties throughout your operations, including:\u003Cbr>\n&nbsp; &nbsp; o a system that ensures each staff member receives training to enable them to properly perform each of their job duties in advance of performing job tasks\u003Cbr>\n&nbsp; &nbsp; o a review of your training curriculum, including courses, timing, frequency, and training effectiveness\u003Cbr>\n&nbsp; &nbsp; o supervision to determine ongoing adherence of staff to procedures and proper practices\u003Cbr>\n&nbsp; &nbsp; o provisions for retraining in response to deficient performance or, when appropriate, re-evaluating whether the individual has the appropriate qualifications and expertise (training, education, skills) for the type and complexity of their assigned work\u003Cbr>\n&nbsp; &nbsp; o training of supervisors and managers in CGMPs\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not ensure that incoming lots of active pharmaceutical ingredient (API) and packaging materials were suitable for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>Your firm released API for use in drug manufacturing based on a component supplier’s certificate of analysis (COA), although you neither established the reliability of the analysis through appropriate validation nor performed identity testing. Notably, examples included two lots of carboxy methyl cellulose sodium API used to manufacture Artificial Tears batches distributed to the U.S. market.\u003C\u002Fp>\n\n\u003Cp>You also failed to adequately test primary packaging materials, including caps and plugs, used in the Artificial Tears container-closure system. For example, between 2019 and 2022, you received \u003Cstrong>(b)(4)\u003C\u002Fstrong> shipments of caps and plugs supplied as sterile from a vendor and released them for use based on the supplier’s COA without adequate testing.\u003C\u002Fp>\n\n\u003Cp>Identity testing for each component lot used in drug product manufacturing is required, and you may only rely on COA for other component attributes if you validate the supplier’s test results to ensure their reliability at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>A drug product produced by aseptic processing can become contaminated not only by unacceptable practices in the manufacturing operation, but also due to the use of one or more defective components, containers, or closures.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate for reasons that include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• You fail to indicate that all existing and new suppliers will be qualified.\u003C\u002Fp>\n\n\u003Cp>• It lacks details on procedural revisions to be made, including how you intend to establish and maintain assurance of the reliability of your supplier’s COA.\u003C\u002Fp>\n\n\u003Cp>• It also lacks details on your retrospective testing, including the scope of materials to be tested, sampling and testing methods, and how you intend to ensure that incoming materials are suitable for their intended use.\u003C\u002Fp>\n\n\u003Cp>We also note that you listed drug products with FDA as being manufactured at your facility and intended for distribution in the United States, including paracetamol syrup, clotrimazole 1%, and Diaprene Children Maximum Topical Creams, that contain components with a high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination, such as glycerin and propylene glycol. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol \u003C\u002Fem>to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination (“high-risk drug components”), at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003Cbr>\n\u003Cbr>\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fp>\n\n\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\n\n\u003Cp>• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all potentially affected finished drug product batches for the presence of DEG and EG.\u003C\u002Fp>\n\n\u003Cp>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including but not limited to glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including but not limited to ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas and an adequate system for cleaning and disinfecting the room to produce aseptic conditions (21 CFR 211.42(c)(10)(iv) and 211.42(c)(10)(v)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Sterilization and Cleaning\u003C\u002Fem>\u003Cbr>\n\u003Cbr>\nYou failed to adequately sterilize and clean your equipment used for drug product manufacturing, for example:\u003C\u002Fp>\n\n\u003Cp>A. You failed to ensure that all equipment with direct product contact was sterilized. During the inspection, you were not able to provide records showing sterilization of product contact equipment on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Line,” including the filling \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> tubing, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowls. Review of sterilization records revealed that you only documented that garments and tools were sterilized. You also lacked written procedures describing sterilization of the manufacturing equipment.\u003C\u002Fp>\n\n\u003Cp>B. You failed to adequately clean the equipment used to aseptically produce Artificial Tears. Significantly, our investigators observed visible grease-like residue on product contact surfaces of your filling machine after they had been cleaned.\u003C\u002Fp>\n\n\u003Cp>You also lacked written procedures and other documentation describing cleaning of the manufacturing equipment.\u003C\u002Fp>\n\n\u003Cp>C. You lacked cleaning validation studies for the shared manufacturing equipment on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Line.”\u003C\u002Fp>\n\n\u003Cp>Inadequately cleaned and maintained equipment can lead to cross-contamination and poor quality drug products.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate for reasons that include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• You fail to provide cleaning procedures or cleaning validation protocols. In addition, no commitment is made to comprehensively evaluate the suitability of your filling machine and other equipment for the manufacture of sterile drug products.\u003C\u002Fp>\n\n\u003Cp>• You fail to provide details of your proposed testing of retain samples.\u003C\u002Fp>\n\n\u003Cp>• You fail to provide explanations for the conflicting information provided to FDA investigators during the inspection. For example, investigators were initially told that \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowls on the filling line were not cleaned or sterilized. These statements were later retracted; however, you were unable to provide sufficient information to support claims that \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowls were cleaned and sterilized.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Monitoring Environmental Conditions\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your environmental monitoring (EM) program (including personnel monitoring (PM)) was inadequate for classified areas used to produce sterile ophthalmic drug products. For example, non-viable air samples were not collected inside the Grade A filling zone or the Grade B surrounding areas during active filling, you lacked studies to demonstrate that residual disinfectant would not interfere with the swabs used for viable surface monitoring, and you lacked identification data on isolates recovered from EM and PM sampling.\u003Cbr>\n\u003Cbr>\nVigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to, heightened emphasis on well-timed sampling to appropriately monitor batch manufacturing conditions.\u003C\u002Fp>\n\n\u003Cp>In your response, you mention a limited number of environmental samples taken in January 2023 were sent to a third-party laboratory and these samples did not reveal Pseudomonas aeruginosa in your environment. This response is inadequate. The last batches of Artificial Tears shipped to the United States had been manufactured many months before (in April 2022) your limited sampling was conducted, according to records provided by your firm. Environmental sampling that occurs several months after batch manufacture is of little temporal significance. There is also minimal scientific value in testing sterile drug manufacturing areas solely for the presence of a single microbial species. You also had batch retain samples tested by a third-party laboratory and you reported in your response that these samples did not fail sterility testing. However, it is not unexpected that sterility testing of retains of otherwise contaminated batches may pass sterility testing because of the non-uniform nature of microbiological contamination. As noted above, many of your firm’s batches were found to be non-sterile upon FDA testing and were associated with grave adverse events.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fp>\n\n\u003Cp>• A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fp>\n\n\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to, a plan to fully remediate these programs. For example, describe changes to equipment, procedures, and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Provide an updated timeline for implementation of your program, including a summary of the CAPA steps you will be undertaking to ensure effective remediation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods, and you also failed to conduct appropriate laboratory testing to determine whether each batch of drug product purporting to be sterile conforms to such requirements (21 CFR 211.165(e) and 211.167(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate sterility testing, for example:\u003C\u002Fp>\n\n\u003Cp>A. You failed to show that your sterility test method was suitable to detect microorganisms in your ophthalmic drug products.\u003C\u002Fp>\n\n\u003Cp>Method suitability testing ensures the method can reliably determine the presence of microbial growth in the product. Method validation and verification is necessary to support reliable determinations of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that the data provided to customers was an accurate reflection of pharmaceutical product quality and safety.\u003C\u002Fp>\n\n\u003Cp>B. You lacked growth promotion tests of the media used for media fills and personnel monitoring.\u003C\u002Fp>\n\n\u003Cp>The validity of your microbiological testing cannot be ensured without appropriate testing of media.\u003C\u002Fp>\n\n\u003Cp>In your response, you make commitments to review your sterility testing and other analytical method validations, initiate sterility method verification, and revise your media preparation procedures. Your response is inadequate because you fail to provide revised procedures and you do not address your failure to perform adequate sterility testing on your distributed finished drug products.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>• A detailed risk assessment addressing the hazards posed by distributing contaminated drug products.\u003C\u002Fp>\n\n\u003Cp>• Complete investigations into all batches with confirmed and potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fp>\n\n\u003Cp>• All chemical and microbial test methods used to analyze each of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacture of your drug products. For example:\u003C\u002Fp>\n\n\u003Cp>A. You failed to perform adequate batch release to ensure the acceptability of all batches of Artificial Tears, prior to release for the U.S. market.\u003C\u002Fp>\n\n\u003Cp>B. Your quality system does not adequately ensure the accuracy and integrity of data to support the quality of the drugs you manufacture. For example, your firm permitted the unacceptable practice of using pre-filled batch release documents.\u003C\u002Fp>\n\n\u003Cp>C. You failed to follow your change management procedure. The impact of the change to the specification for the inner cap (plug) used as part of your Artificial Tears container-closure system to a plug “with prehole” was not evaluated.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will perform an impact assessment for all change controls initiated. Your response is inadequate for reasons that include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• You do not assess all records potentially affected by lapses in data integrity. You also do not assess how poor documentation practices affected distributed drug product nor how you could strengthen QU oversight. You also do not provide copies of the missing batch release documents you indicated that you have now recovered.\u003C\u002Fp>\n\n\u003Cp>• You do not perform a review and impact assessment for changes made outside of your change management system and not previously evaluated.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP-compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Your firm should retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>A. A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>B. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>C. A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, EZRICARE Artificial Tears and Delsam Pharma’s ARTIFICIAL TEARS are intended for use as ophthalmic demulcents, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT is intended for use as an ophthalmic emollient.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your product labeling that provide evidence of the intended uses (as defined by 21 CFR 201.128) of your products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>EZRICARE Artificial Tears\u003Cbr>\n“Drug Facts . . . Uses . . . ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind or sun” [from your product’s label]\u003C\u002Fp>\n\n\u003Cp>Delsam Pharma’s ARTIFICIAL TEARS\u003Cbr>\n“Drug Facts . . . Uses . . . ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind or sun” [from your product’s label]\u003C\u002Fp>\n\n\u003Cp>Delsam Pharma’s ARTIFICIAL EYE OINTMENT\u003Cbr>\n“Drug Facts . . . Uses . . . For use as a lubricant to prevent further irritation or to relieve dryness of the eyes.” [from your product’s label]\u003C\u002Fp>\n\n\u003Cp>EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because they are not sterile. 21 CFR 200.50 states that all preparations offered or intended for ophthalmic use should be sterile, and if not are deemed misbranded under section 502(j) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, FDA analysis of samples of EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT determined that these products were contaminated with microorganisms. For example, microorganisms in your products included but were not limited to the following: EZRICARE Artificial Tears contained \u003Cem>Pseudomonas\u003C\u002Fem> species, Delsam Pharma’s ARTIFICIAL TEARS contained \u003Cem>Bacillus\u003C\u002Fem> species, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT contained \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex. There is a reasonable probability that instillation of a bacterially contaminated eye product into the eye may cause a range of ocular infections, from minor to serious, vision-threatening infections which could progress in some cases to life-threatening systemic bacterial infection. Therefore, EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j).\u003C\u002Fp>\n\n\u003Cp>In addition, Delsam Pharma’s ARTIFICIAL EYE OINTMENT is further misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. Specifically, the principal display panel (PDP) of the product label purports the product to be “sterile.” However, FDA analysis of samples of Delsam Pharma’s ARTIFICIAL EYE OINTMENT determined that it was contaminated with microorganisms including \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex. Therefore, the labeling for Delsam Pharma’s ARTIFICIAL EYE OINTMENT is false or misleading, because the product is not in fact sterile for its intended use as an ophthalmic emollient drug product, and thus the product is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Recalls\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On January 30, 2023, FDA held a teleconference with you. We recommended you consider removing all batches of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears in distribution from the U.S. market. On February 2, 2023, you initiated a voluntary recall of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears based on bacterial contamination and CGMP concerns discussed with your firm. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-pharma-healthcare-issues-voluntary-nationwide-recall-artificial-tears-lubricant-eye-drops-due.\u003C\u002Fp>\n\n\u003Cp>On February 22, 2023, FDA held another teleconference with you. We recommended you remove batch H29 of Delsam Pharma’s Artificial Eye Ointment in U.S. distribution. On February 24, 2023, you initiated a voluntary recall of Delsam Pharma’s Artificial Eye Ointment due to non-sterility. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-pharma-healthcare-issues-voluntary-nationwide-recall-delsam-pharma-artificial-eye-ointment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to suspend production of drugs for the U.S. market.\u003C\u002Fp>\n\n\u003Cp>Given the egregious violations of CGMP at your facility, if you plan to resume drug manufacturing operations for the U.S. market, decide to transfer your ownership, contract out any processes, or move to a new location, notify this office.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34, to assist your firm in meeting drug CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to a severe lack of effective production oversight of facilities and equipment, we found your quality unit is not enabled to exercise proper authority and has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on January 3, 2023, after your response to our 704(a)(4) Request for Records sent to you on November 15, 2022, demonstrated CGMP violations related to controls for DEG\u002FEG in high-risk components used in your drugs.\u003C\u002Fp>\n\n\u003Cp>The inspectional findings and sample results detailed above further demonstrate your firm’s noncompliance.\u003C\u002Fp>\n\n\u003Cp>Your firm remains on Import Alert 66-40.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Global Pharma Healthcare Private Limited, A-9 SIDCO Pharmaceutical Complex, Thiruporur, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012323885 and ATTN: Carrie Ann Plucinski.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 200.50(a)(2) states, in relevant part, “…liquid preparations offered or intended for ophthalmic use that are not sterile may be regarded as adulterated…”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> National Center for Biotechnology Information (NCBI)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 200.50(a)(2) states, in relevant part, “liquid preparations offered or intended for ophthalmic use that are not sterile…may be deemed misbranded within the meaning of section 502(j) of the FD&amp;C Act. This ruling is extended to affect all preparations for ophthalmic use. By this regulation, this ruling is applicable to ophthalmic preparations that are regulated as drugs.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. A.R. Venkatesh\n\nRecipient Title\n\nChief Executive Officer\n\nGlobal Pharma Healthcare Private Limited\n\nA-9 SIDCO Pharmaceutical Complex\n\nThiruporur 603110\n\nTamil Nadu\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-03\n\nOctober 20, 2023\n\nDear Dr. Venkatesh:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Global Pharma Healthcare Private Limited, FEI 3012323885, at A-9 SIDCO Pharmaceutical Complex, Thiruporur, from February 20 to March 2, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nBecause your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)1.\n\nIn addition, EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), and Delsam Pharma’s ARTIFICIAL EYE OINTMENT is further misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nPseudomonas aeruginosa Outbreak and FDA Testing of Samples\n\nIn December 2022, FDA began collaborating with the Center for Disease Control and Prevention (CDC) on an investigation into the multistate outbreak of antibiotic-resistant Pseudomonas aeruginosa infections that ultimately affected more than 80 patients and led to 4 patient deaths and at least 14 cases of vision loss. As part of this investigation, FDA collected finished product samples of Artificial Tears and Artificial Eye Ointment batches that were manufactured by your facility, and we sent the samples for sterility testing at FDA laboratories. Our analysis of intact (unopened) units found that 18 batches of Artificial Tears were non-sterile. In addition, we also sampled a batch of your Artificial Eye Ointment product, and this batch was also found to be non-sterile. The testing of these intact units revealed that your ophthalmic drug products were intrinsically contaminated with microorganisms. Microbiological isolates from the non-sterile samples were further characterized using whole genome sequencing and compared to isolates in a national database.2 Pseudomonas aeruginosa isolates from three different batches of intact Artificial Tears samples collected by FDA were found to be close genetic matches to more than 85 clinical isolates associated with this outbreak. These test results demonstrate that these lots are adulterated under section 501(a)(1) of the FD&C Act, in that they have been contaminated with filth, and rendered injurious to health.\n\nSignificantly, the pervasive contamination of your drug products, as indicated by FDA sample results, also demonstrates that all drugs made at your facility are adulterated under section 501(a)(2)(A) of the FD&C Act as they have been manufactured under insanitary conditions.\n\nIn addition, two intact samples of Artificial Tears from different batches were found to contain visible, foreign particles.\n\nCGMP Violations\n\nWe reviewed your March 22, 2023, response to our Form FDA 483 in detail. During our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nInadequate Equipment and Processes\n\nA. You lacked adequate scientific evidence that the aseptic filling machine used for manufacture of Artificial Tears was suitable for its intended use. Your qualification report was inadequate, including a lack of data on any batches filled as part of the qualification study. Further, all batches of Artificial Tears distributed to the U.S. market were manufactured using filling machine parameters that were outside the design specifications of the equipment.\n\nB. You lacked validation of the processes used to manufacture your aseptically filled Artificial Tears, for example:\n\n• You failed to validate methods that were intended to render your ophthalmic drug products sterile. Specifically, you lacked a study to show the (b)(4) performed on your Artificial Tears product using a (b)(4) can reliably achieve sterilization.\n\n• Your media fill program lacked assurance that aseptic processing operations are appropriately performed to prevent microbial contamination. Our inspection found that you failed to perform appropriate and sufficient media fills studies, for example:\n\no Your media fills failed to adequately simulate the commercial aseptic manufacturing operation. Interventions were not simulated sufficiently or accurately. In addition, you have a manually intensive line with minimal barrier protection where the possibility of contamination is greater. Despite this, you filled (b)(4)-(b)(4)% of the production batch size during media fills.\n\no Manufacturing lines used to produce the Artificial Tears and Artificial Eye Ointment products were not qualified by three successful media fills.\n\no You removed integral units (i.e., units with intact container-closure systems) from media fills without adequate justification and failed to incubate all integral units for the full (b)(4) period.\n\no The personnel responsible for visual inspection of media-filled units lacked appropriate training and qualification.\n\nC. You lacked meaningful airflow pattern studies for your aseptic processing lines. The studies were not performed under dynamic conditions and lacked simulation of interventions and other routine activities that occur during aseptic manufacturing operations.\n\nD. Your firm also shipped an ointment product to the United States that was manufactured using a (b)(4) sterilization process. You failed to ensure the (b)(4) process employed by your contractor to sterilize your Artificial Eye Ointment was validated.\n\nYour response is inadequate, including the following:\n\n• You lack details of your internal investigation into the product contamination. Your investigation is not comprehensive, including but not limited to, a lack of descriptions of the activities performed and root cause analysis. You also lack details on sampling and laboratory methods used for environmental and other tests.\n\n• There is a lack of detail relating to future dynamic airflow pattern studies; heating, ventilation, and air conditioning (HVAC) system qualification; or media fill procedural revisions.\n\n• You also fail to include a commitment to validate the (b)(4) sterilization process and sterility test methods for the Artificial Eye Ointment products.\n\nLack of Container Closure Integrity\n\nYou lacked evidence of reliable container closure integrity for your multi-use ophthalmic products that purport to be sterile. While visual inspections revealed leakers during batch manufacture, there was no assurance that your visual inspection procedure was adequate.\n\nYour product distributors received complaints of leaking Artificial Tears and Artificial Eye Ointment units. FDA’s laboratory performed container closure integrity testing of Artificial Eye Ointment, batch H29, manufactured at your facility. FDA tested 20 units, and 1 unit was found to allow microbiological ingress, which further confirmed that your container-closure system lacks integrity and is insufficient for maintaining sterility. Notably, batch H29 was also found to be non-sterile through FDA testing.\n\nAll sterile drugs must be packaged using a container-closure system that protects product integrity for the duration of its shelf-life. Maintenance of product integrity throughout stresses of its manufacture, storage, distribution, and consumer use is critical to product quality and safety. Loss of container-closure integrity is a direct cause of non-sterility of medicines.\n\nIn your response, you state you will perform container-closure integrity testing using a dye ingress method for your Artificial Tears product and a comprehensive sterility assessment. Your response is inadequate because your container-closure integrity testing protocol does not extend to Artificial Eye Ointment. In addition, you do not sufficiently address the sensitivity of your dye ingress method. The sensitivity of the method to be employed for your study is unclear, and you do not indicate whether it is capable of correlating with detection of bacteria comparable in size to Pseudomonas aeruginosa. Furthermore, your response does not include details on the comprehensive sterility assessment.\n\nInadequate Formulation for Artificial Tears and Artificial Eye Ointment\n\nYou manufactured multi-dose, over-the-counter (OTC) ophthalmic drug products for the product owners, EzriCare LLC, and Delsam Pharma LLC. These products lacked antimicrobial properties to preserve the formulation. Significantly, your firm also marketed this multi-dose product without performing antimicrobial effectiveness studies. It is essential that multi-dose ophthalmic drug products contain one or more suitable substances that will preserve the product and minimize the hazard of injury resulting from incidental contamination during use.\n\nIn your response, you state that antimicrobial effectiveness testing (AET) will be initiated for your Artificial Tears product, and you will use these studies to determine if a suitable preservative will be added to the formulation. Your response is inadequate because you do not explain why you failed to perform AET studies prior to launch of your drug product, and how you will correct such fundamental flaws in your product development program. You also make no commitment to conduct AET for the Artificial Eye Ointment formulation. In addition, although your protocol indicates that you follow the United States Pharmacopeia (USP), the acceptance criteria in the Artificial Tears protocol is less stringent and not in alignment with USP \u003C51> Antimicrobial Effectiveness Testing.\n\nInadequate Gowning Practices & Operator Qualification\n\nCleanroom operators lacked adequate gowning and qualification for performing aseptic operations. Your deficient practices and procedures placed products at high risk for contamination, for example:\n\nA. A gowning demonstration revealed that cleanroom operators do not don sterile goggles and therefore have exposed skin around their eyes during aseptic operations.\n\nB. Cleanroom garments were not suitable for their intended use. For example, garments indicated to be clean were observed to be stained, worn out, and stored improperly. In addition, your firm re-used cleanroom garments for an unspecified number of times without tracking or validation.\n\nC. You lacked written procedures and a training program on proper aseptic behavior and gowning for cleanroom operators. You also lacked evidence that all cleanroom operators are qualified through participation in a media fill, and the microbiological limit set in your gowning validation procedure is unsuitable for aseptic operations.\n\nD. You lacked written procedures and a training program on proper aseptic behavior and gowning for cleanroom operators. You also lacked evidence that all cleanroom operators were qualified through participation in a media fill and justification for the microbiological limits used in your aseptic processing operator gowning qualification procedure (i.e., no more than (NMT) (b)(4) colony forming units (cfu) for each gowning location). You also lacked a commitment to systematically review staff qualifications and competencies throughout your operation, including but not limited to, ensuring an effective CGMP training program.\n\nIn your response, you state that gowning qualification will be performed through media fills, and an in-house study will evaluate the impact of repeated sterilization cycles on cleanroom garments to establish an acceptable number of sterilization cycles. Your response is inadequate. You lack a comprehensive review of all aspects of personnel gowning, the qualification program, aseptic technique, cleanroom behavior, and an examination of the role of people as a contamination hazard in your processes. To further illustrate, you continue to lack substantive actions to implement sterile goggles, enhance practices to prevent sterile gown contamination, gowning qualification criteria (e.g., sampling requirements, location descriptions, acceptance limits with justifications), and many other basic elements of a compliant sterile facility. Your response also fails to address how your inadequate gowning practices impacted your sterile drug products.\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nIn response to this letter, provide the following:\n\n• Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\n• A detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility. Explain how your corrective action and preventive action (CAPA) will robustly remediate your deficient sterile manufacturing operation. Also describe your plans for qualification and validation of your comprehensively remediated facility, processes and equipment.\n\n• A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n• Your plan to ensure that inspection and other quality control methods for container-closure systems, including but not limited to opaque bottles and ointment tubes, can robustly detect integrity breaches.\n\n• A comprehensive, independent assessment of the qualifications and competencies of staff to conduct their job duties throughout your operations, including:\n\no a system that ensures each staff member receives training to enable them to properly perform each of their job duties in advance of performing job tasks\n\no a review of your training curriculum, including courses, timing, frequency, and training effectiveness\n\no supervision to determine ongoing adherence of staff to procedures and proper practices\n\no provisions for retraining in response to deficient performance or, when appropriate, re-evaluating whether the individual has the appropriate qualifications and expertise (training, education, skills) for the type and complexity of their assigned work\n\no training of supervisors and managers in CGMPs\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou did not ensure that incoming lots of active pharmaceutical ingredient (API) and packaging materials were suitable for use in manufacturing.\n\nYour firm released API for use in drug manufacturing based on a component supplier’s certificate of analysis (COA), although you neither established the reliability of the analysis through appropriate validation nor performed identity testing. Notably, examples included two lots of carboxy methyl cellulose sodium API used to manufacture Artificial Tears batches distributed to the U.S. market.\n\nYou also failed to adequately test primary packaging materials, including caps and plugs, used in the Artificial Tears container-closure system. For example, between 2019 and 2022, you received (b)(4) shipments of caps and plugs supplied as sterile from a vendor and released them for use based on the supplier’s COA without adequate testing.\n\nIdentity testing for each component lot used in drug product manufacturing is required, and you may only rely on COA for other component attributes if you validate the supplier’s test results to ensure their reliability at appropriate intervals.\n\nA drug product produced by aseptic processing can become contaminated not only by unacceptable practices in the manufacturing operation, but also due to the use of one or more defective components, containers, or closures.\n\nYour response is inadequate for reasons that include, but are not limited to, the following:\n\n• You fail to indicate that all existing and new suppliers will be qualified.\n\n• It lacks details on procedural revisions to be made, including how you intend to establish and maintain assurance of the reliability of your supplier’s COA.\n\n• It also lacks details on your retrospective testing, including the scope of materials to be tested, sampling and testing methods, and how you intend to ensure that incoming materials are suitable for their intended use.\n\nWe also note that you listed drug products with FDA as being manufactured at your facility and intended for distribution in the United States, including paracetamol syrup, clotrimazole 1%, and Diaprene Children Maximum Topical Creams, that contain components with a high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination, such as glycerin and propylene glycol. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination (“high-risk drug components”), at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all potentially affected finished drug product batches for the presence of DEG and EG.\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including but not limited to glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including but not limited to ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\n\n3. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas and an adequate system for cleaning and disinfecting the room to produce aseptic conditions (21 CFR 211.42(c)(10)(iv) and 211.42(c)(10)(v)).\n\nSterilization and Cleaning\n\nYou failed to adequately sterilize and clean your equipment used for drug product manufacturing, for example:\n\nA. You failed to ensure that all equipment with direct product contact was sterilized. During the inspection, you were not able to provide records showing sterilization of product contact equipment on the “(b)(4) Line,” including the filling (b)(4), (b)(4) tubing, and (b)(4) bowls. Review of sterilization records revealed that you only documented that garments and tools were sterilized. You also lacked written procedures describing sterilization of the manufacturing equipment.\n\nB. You failed to adequately clean the equipment used to aseptically produce Artificial Tears. Significantly, our investigators observed visible grease-like residue on product contact surfaces of your filling machine after they had been cleaned.\n\nYou also lacked written procedures and other documentation describing cleaning of the manufacturing equipment.\n\nC. You lacked cleaning validation studies for the shared manufacturing equipment on the “(b)(4) Line.”\n\nInadequately cleaned and maintained equipment can lead to cross-contamination and poor quality drug products.\n\nYour response is inadequate for reasons that include, but are not limited to, the following:\n\n• You fail to provide cleaning procedures or cleaning validation protocols. In addition, no commitment is made to comprehensively evaluate the suitability of your filling machine and other equipment for the manufacture of sterile drug products.\n\n• You fail to provide details of your proposed testing of retain samples.\n\n• You fail to provide explanations for the conflicting information provided to FDA investigators during the inspection. For example, investigators were initially told that (b)(4) bowls on the filling line were not cleaned or sterilized. These statements were later retracted; however, you were unable to provide sufficient information to support claims that (b)(4) bowls were cleaned and sterilized.\n\nMonitoring Environmental Conditions\n\nYour environmental monitoring (EM) program (including personnel monitoring (PM)) was inadequate for classified areas used to produce sterile ophthalmic drug products. For example, non-viable air samples were not collected inside the Grade A filling zone or the Grade B surrounding areas during active filling, you lacked studies to demonstrate that residual disinfectant would not interfere with the swabs used for viable surface monitoring, and you lacked identification data on isolates recovered from EM and PM sampling.\n\nVigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to, heightened emphasis on well-timed sampling to appropriately monitor batch manufacturing conditions.\n\nIn your response, you mention a limited number of environmental samples taken in January 2023 were sent to a third-party laboratory and these samples did not reveal Pseudomonas aeruginosa in your environment. This response is inadequate. The last batches of Artificial Tears shipped to the United States had been manufactured many months before (in April 2022) your limited sampling was conducted, according to records provided by your firm. Environmental sampling that occurs several months after batch manufacture is of little temporal significance. There is also minimal scientific value in testing sterile drug manufacturing areas solely for the presence of a single microbial species. You also had batch retain samples tested by a third-party laboratory and you reported in your response that these samples did not fail sterility testing. However, it is not unexpected that sterility testing of retains of otherwise contaminated batches may pass sterility testing because of the non-uniform nature of microbiological contamination. As noted above, many of your firm’s batches were found to be non-sterile upon FDA testing and were associated with grave adverse events.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\n• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\n• A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n• A comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to, a plan to fully remediate these programs. For example, describe changes to equipment, procedures, and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Provide an updated timeline for implementation of your program, including a summary of the CAPA steps you will be undertaking to ensure effective remediation.\n\n4. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods, and you also failed to conduct appropriate laboratory testing to determine whether each batch of drug product purporting to be sterile conforms to such requirements (21 CFR 211.165(e) and 211.167(a)).\n\nYour firm lacked adequate sterility testing, for example:\n\nA. You failed to show that your sterility test method was suitable to detect microorganisms in your ophthalmic drug products.\n\nMethod suitability testing ensures the method can reliably determine the presence of microbial growth in the product. Method validation and verification is necessary to support reliable determinations of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that the data provided to customers was an accurate reflection of pharmaceutical product quality and safety.\n\nB. You lacked growth promotion tests of the media used for media fills and personnel monitoring.\n\nThe validity of your microbiological testing cannot be ensured without appropriate testing of media.\n\nIn your response, you make commitments to review your sterility testing and other analytical method validations, initiate sterility method verification, and revise your media preparation procedures. Your response is inadequate because you fail to provide revised procedures and you do not address your failure to perform adequate sterility testing on your distributed finished drug products.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A detailed risk assessment addressing the hazards posed by distributing contaminated drug products.\n\n• Complete investigations into all batches with confirmed and potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\n\n• All chemical and microbial test methods used to analyze each of your drug products.\n\n5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacture of your drug products. For example:\n\nA. You failed to perform adequate batch release to ensure the acceptability of all batches of Artificial Tears, prior to release for the U.S. market.\n\nB. Your quality system does not adequately ensure the accuracy and integrity of data to support the quality of the drugs you manufacture. For example, your firm permitted the unacceptable practice of using pre-filled batch release documents.\n\nC. You failed to follow your change management procedure. The impact of the change to the specification for the inner cap (plug) used as part of your Artificial Tears container-closure system to a plug “with prehole” was not evaluated.\n\nIn your response, you state you will perform an impact assessment for all change controls initiated. Your response is inadequate for reasons that include, but are not limited to, the following:\n\n• You do not assess all records potentially affected by lapses in data integrity. You also do not assess how poor documentation practices affected distributed drug product nor how you could strengthen QU oversight. You also do not provide copies of the missing batch release documents you indicated that you have now recovered.\n\n• You do not perform a review and impact assessment for changes made outside of your change management system and not previously evaluated.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP-compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nYour firm should retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n\nA. A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nB. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nC. A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\nMisbranded Drug Violations\n\nEZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, EZRICARE Artificial Tears and Delsam Pharma’s ARTIFICIAL TEARS are intended for use as ophthalmic demulcents, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT is intended for use as an ophthalmic emollient.\n\nExamples of claims from your product labeling that provide evidence of the intended uses (as defined by 21 CFR 201.128) of your products as drugs include, but may not be limited to, the following:\n\nEZRICARE Artificial Tears\n\n“Drug Facts . . . Uses . . . ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind or sun” [from your product’s label]\n\nDelsam Pharma’s ARTIFICIAL TEARS\n\n“Drug Facts . . . Uses . . . ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind or sun” [from your product’s label]\n\nDelsam Pharma’s ARTIFICIAL EYE OINTMENT\n\n“Drug Facts . . . Uses . . . For use as a lubricant to prevent further irritation or to relieve dryness of the eyes.” [from your product’s label]\n\nEZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because they are not sterile. 21 CFR 200.50 states that all preparations offered or intended for ophthalmic use should be sterile, and if not are deemed misbranded under section 502(j) of the FD&C Act.3 However, FDA analysis of samples of EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT determined that these products were contaminated with microorganisms. For example, microorganisms in your products included but were not limited to the following: EZRICARE Artificial Tears contained Pseudomonas species, Delsam Pharma’s ARTIFICIAL TEARS contained Bacillus species, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT contained Burkholderia cepacia complex. There is a reasonable probability that instillation of a bacterially contaminated eye product into the eye may cause a range of ocular infections, from minor to serious, vision-threatening infections which could progress in some cases to life-threatening systemic bacterial infection. Therefore, EZRICARE Artificial Tears, Delsam Pharma’s ARTIFICIAL TEARS, and Delsam Pharma’s ARTIFICIAL EYE OINTMENT are misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j).\n\nIn addition, Delsam Pharma’s ARTIFICIAL EYE OINTMENT is further misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. Specifically, the principal display panel (PDP) of the product label purports the product to be “sterile.” However, FDA analysis of samples of Delsam Pharma’s ARTIFICIAL EYE OINTMENT determined that it was contaminated with microorganisms including Burkholderia cepacia complex. Therefore, the labeling for Delsam Pharma’s ARTIFICIAL EYE OINTMENT is false or misleading, because the product is not in fact sterile for its intended use as an ophthalmic emollient drug product, and thus the product is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nDrug Recalls\n\nOn January 30, 2023, FDA held a teleconference with you. We recommended you consider removing all batches of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears in distribution from the U.S. market. On February 2, 2023, you initiated a voluntary recall of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears based on bacterial contamination and CGMP concerns discussed with your firm. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-pharma-healthcare-issues-voluntary-nationwide-recall-artificial-tears-lubricant-eye-drops-due.\n\nOn February 22, 2023, FDA held another teleconference with you. We recommended you remove batch H29 of Delsam Pharma’s Artificial Eye Ointment in U.S. distribution. On February 24, 2023, you initiated a voluntary recall of Delsam Pharma’s Artificial Eye Ointment due to non-sterility. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fglobal-pharma-healthcare-issues-voluntary-nationwide-recall-delsam-pharma-artificial-eye-ointment.\n\nDrug Production Suspended\n\nWe acknowledge your commitment to suspend production of drugs for the U.S. market.\n\nGiven the egregious violations of CGMP at your facility, if you plan to resume drug manufacturing operations for the U.S. market, decide to transfer your ownership, contract out any processes, or move to a new location, notify this office.\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34, to assist your firm in meeting drug CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit4 of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to a severe lack of effective production oversight of facilities and equipment, we found your quality unit is not enabled to exercise proper authority and has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on January 3, 2023, after your response to our 704(a)(4) Request for Records sent to you on November 15, 2022, demonstrated CGMP violations related to controls for DEG\u002FEG in high-risk components used in your drugs.\n\nThe inspectional findings and sample results detailed above further demonstrate your firm’s noncompliance.\n\nYour firm remains on Import Alert 66-40.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Global Pharma Healthcare Private Limited, A-9 SIDCO Pharmaceutical Complex, Thiruporur, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&C Act, respectively.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012323885 and ATTN: Carrie Ann Plucinski.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n____________________\n\n1 21 CFR 200.50(a)(2) states, in relevant part, “…liquid preparations offered or intended for ophthalmic use that are not sterile may be regarded as adulterated…”\n\n2 National Center for Biotechnology Information (NCBI)\n\n3 21 CFR 200.50(a)(2) states, in relevant part, “liquid preparations offered or intended for ophthalmic use that are not sterile…may be deemed misbranded within the meaning of section 502(j) of the FD&C Act. This ruling is extended to affect all preparations for ophthalmic use. By this regulation, this ruling is applicable to ophthalmic preparations that are regulated as drugs.”\n\n4 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Global Pharma Healthcare Private Limited","global-pharma-healthcare-private-limited-657325-10202023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-pharma-healthcare-private-limited-657325-10202023","2026-10-26T08:08:46.716657+00:00","2023-11-14","657325","Dr. A.R. Venkatesh","2026-08-20T00:31:33.354+00:00","2023-10-20",{"id":75,"raw":76,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":66,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":80,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},1681,[77,78,79,80,81,13,13,13],"\u003Ctime datetime=\"2023-12-26T14:20:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-21T05:00:00Z\">12\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwipro-unza-singapore-private-limited-660735-12212023\">Wipro Unza Singapore Private, Limited\u003C\u002Fa>","Drug","Refusal to Provide Access to and Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Deepak Chandran\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Wipro Unza Singapore Private, Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>163 Penang Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>#04-01 Winsland House II\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>238463\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Singapore\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:deepak.chandran@wipro.com\"> deepak.chandran@wipro.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Drug\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-24-07\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 21, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Chandran:\u003C\u002Fp>\n\n\u003Cp>Your firm was registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products including hand sanitizers, specifically, Aiken Hand Sanitizer. A review of import records showed multiple shipments of OTC drug products into the United States which declared WIPRO Consumer Care Vietnam Company, Limited as the drug manufacturer.\u003C\u002Fp>\n\n\u003Cp>On June 16, 2022, the FDA sent a request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered. A second request was sent via e-mail on July 7, 2022, followed by a telephone conversation with your registered United States Agent on September 2, 2022, regarding this matter. The Agency sent a follow-up written request for such records and other information on October 7, 2022. Delivery to you was confirmed by the shipper, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>On October 10, 2022, your Head of Legal e-mailed FDA stating that “our hand sanitizer product is not exported” to the United States, “nor do we have any plans for distribution” in the United States. However, our import records showed your firm had shipped drug product to the United States. On May 4, 2023, FDA held a teleconference with you and your consultant, where you committed to collecting additional information regarding your firm’s registration with the FDA. Your consultant provided a letter to FDA, dated May 29, 2023, stating that your firm contracted directly with a distributor, specifically to register your firm with the FDA and distribute products to the United States market. This letter is in contrast to your Head of Legal’s original communication to FDA.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your registration with FDA expired on December 31, 2022, and your consultant communicated with the Agency that you would not ship drug products either directly or indirectly to the United States.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>On July 5, 2023, FDA notified the public that you failed to respond to multiple FDA requests for records related to drug manufacturing and product quality, at the following website:\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fp>\n\n\u003Cp>FDA also placed all drugs and drug products manufactured by your firm on Import Alert 66-79 on August 11, 2023.\u003C\u002Fp>\n\n\u003Cp>Until FDA is able to confirm compliance with Current Good Manufacturing Practice (CGMP) and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at WIPRO Consumer Care Vietnam Company, Limited, FEI 3015596082 located at 7 Street No. 4, Viet Nam, Singapore Industrial Zone, Binh HOA Ward, Thuan An, Binh Duong Province, Vietnam into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015596082 and ATTN: Yasamin Ameri.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nRegistered U.S. Agent:\u003Cbr>\nLiberty Management Group, Ltd.\u003Cbr>\nmanoj@libertymanagement.us\u003C\u002Fp>\n\n\u003Cp>Dnyanesh Sabnis, General Lead Counsel\u003Cbr>\ndnyanesh.sabnis@wipro.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDeepak Chandran\n\nRecipient Title\n\nDirector\n\nWipro Unza Singapore Private, Limited\n\n163 Penang Rd\n\n#04-01 Winsland House II\n\n238463\n\nSingapore\n\ndeepak.chandran@wipro.com\n\nIssuing Office:\n\nDrug\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWarning Letter 320-24-07\n\nDecember 21, 2023\n\nDear Mr. Chandran:\n\nYour firm was registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products including hand sanitizers, specifically, Aiken Hand Sanitizer. A review of import records showed multiple shipments of OTC drug products into the United States which declared WIPRO Consumer Care Vietnam Company, Limited as the drug manufacturer.\n\nOn June 16, 2022, the FDA sent a request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered. A second request was sent via e-mail on July 7, 2022, followed by a telephone conversation with your registered United States Agent on September 2, 2022, regarding this matter. The Agency sent a follow-up written request for such records and other information on October 7, 2022. Delivery to you was confirmed by the shipper, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nOn October 10, 2022, your Head of Legal e-mailed FDA stating that “our hand sanitizer product is not exported” to the United States, “nor do we have any plans for distribution” in the United States. However, our import records showed your firm had shipped drug product to the United States. On May 4, 2023, FDA held a teleconference with you and your consultant, where you committed to collecting additional information regarding your firm’s registration with the FDA. Your consultant provided a letter to FDA, dated May 29, 2023, stating that your firm contracted directly with a distributor, specifically to register your firm with the FDA and distribute products to the United States market. This letter is in contrast to your Head of Legal’s original communication to FDA.\n\nWe acknowledge your registration with FDA expired on December 31, 2022, and your consultant communicated with the Agency that you would not ship drug products either directly or indirectly to the United States.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nOn July 5, 2023, FDA notified the public that you failed to respond to multiple FDA requests for records related to drug manufacturing and product quality, at the following website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nFDA also placed all drugs and drug products manufactured by your firm on Import Alert 66-79 on August 11, 2023.\n\nUntil FDA is able to confirm compliance with Current Good Manufacturing Practice (CGMP) and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at WIPRO Consumer Care Vietnam Company, Limited, FEI 3015596082 located at 7 Street No. 4, Viet Nam, Singapore Industrial Zone, Binh HOA Ward, Thuan An, Binh Duong Province, Vietnam into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015596082 and ATTN: Yasamin Ameri.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCc:\n\nRegistered U.S. Agent:\n\nLiberty Management Group, Ltd.\n\nmanoj@libertymanagement.us\n\nDnyanesh Sabnis, General Lead Counsel\n\ndnyanesh.sabnis@wipro.com","Wipro Unza Singapore Private, Limited","wipro-unza-singapore-private-limited-660735-12212023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwipro-unza-singapore-private-limited-660735-12212023","2026-10-26T08:10:32.371543+00:00","2023-12-26","660735","Deepak Chandran","2026-08-20T00:25:34.352+00:00","Via Email","2023-12-21",{"id":95,"raw":96,"subject":39,"body_html":100,"body_text":101,"firm_name":102,"letter_id":103,"created_at":104,"fei_number":19,"letter_url":105,"updated_at":106,"action_type":22,"case_status":23,"posted_date":107,"marcs_cms_no":108,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":109,"body_fetched_at":110,"delivery_method":92,"recipient_title":19,"reference_number":111,"action_taken_date":112,"medical_device_id":19,"response_letter_date":19},1223,[97,98,99,11,38,13,13,13],"\u003Ctime datetime=\"2024-10-08T13:20:00Z\">10\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-24T04:00:00Z\">09\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024\">MMC Healthcare Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-62\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nageswara Rao Gupta Manepalli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MMC Healthcare Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>34-B Sidco Industrial Estate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thirumazhisai, Chennai\u003C\u002Fspan> \u003Cspan>600124\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ceo@mmchealthcareltd.com\"> ceo@mmchealthcareltd.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-62\u003C\u002Fp>\n\n\u003Cp>September 24, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Manepalli:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 18, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection of your facility our Investigator observed that your 2021 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research &amp; Development Manager, and Production Manager admitted to participating in these practices.\u003C\u002Fp>\n\n\u003Cp>Review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Capsules \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\u003C\u002Fp>\n\n\u003Cp>Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>Also describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003Cbr>\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it does not provide sufficient details describing:\u003C\u002Fp>\n\n\u003Cp>• Timeframe for your corrective action.\u003Cbr>\n• Security features of your updated UV-Vis computer system.\u003Cbr>\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\u003Cbr>\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\u003Cbr>\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\u003C\u002Fp>\n\n\u003Cp>It is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\u003Cbr>\n&nbsp; o An evaluation of the impact of this violation.\u003Cbr>\n&nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\u003Cbr>\n&nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\u003Cbr>\n&nbsp; o A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; o System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; o Timeline for the implementation and qualification of your updated UV-Vis software.\u003Cbr>\n&nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; o Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\u003Cbr>\n&nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; o Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; o Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your \u003Cem>E. coli\u003C\u002Fem> test method for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\u003C\u002Fp>\n\n\u003Cp>Test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution within expiry using the revised method, all of which passed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>\n&nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; o A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\u003Cbr>\n&nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 6, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-24-62\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nageswara Rao Gupta Manepalli\n\nRecipient Title\n\nManaging Director\u002FCEO\n\nMMC Healthcare Ltd.\n\n34-B Sidco Industrial Estate\n\nThirumazhisai, Chennai 600124\n\nTamil Nadu\n\nIndia\n\nceo@mmchealthcareltd.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-62\n\nSeptember 24, 2024\n\nDear Mr. Manepalli:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 18, 2024 response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nDuring the inspection of your facility our Investigator observed that your 2021 (b)(4) Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research & Development Manager, and Production Manager admitted to participating in these practices.\n\nReview of the (b)(4) Capsules (b)(4) mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\n\nIn your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\n\nYour response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\n\nData integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\n\nIn your response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAlso describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\n\nIn your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\n\nYour response is inadequate because it does not provide sufficient details describing:\n\n• Timeframe for your corrective action.\n\n• Security features of your updated UV-Vis computer system.\n\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\n\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\n\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\n\nIt is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\n\no An evaluation of the impact of this violation.\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\n\no A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Timeline for the implementation and qualification of your updated UV-Vis software.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\n\no A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\n\no Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\n\n3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYou did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your E. coli test method for (b)(4) Solution and (b)(4) Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\n\nTest methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\n\nIn your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of (b)(4) Solution within expiry using the revised method, all of which passed.\n\nYour response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 6, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nArticles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","MMC Healthcare Ltd.","mmc-healthcare-ltd-684644-09242024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024","2026-10-26T08:09:26.775337+00:00","2024-10-08","684644","Mr. Nageswara Rao Gupta Manepalli","2026-08-19T22:31:41.964+00:00","320-24-62","2024-09-24",{"id":114,"raw":115,"subject":121,"body_html":122,"body_text":123,"firm_name":124,"letter_id":125,"created_at":44,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":130,"closeout_date":19,"issuing_office":119,"recipient_name":131,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":134,"action_taken_date":135,"medical_device_id":19,"response_letter_date":19},697,[116,117,118,119,120,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-15T04:00:00Z\">08\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnate-healthcare-institute-695592-08152025\">Innate Healthcare Institute\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-695592\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Travis Whitney, NMD, DAASCP, MSc, MSAc \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Chief Medical Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Innate Healthcare Institute\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4835 East Cactus Road, Suite 140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85254\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@innatehealthcare.org\"> info@innatehealthcare.org \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 15, 202\u003C\u002Fp>\u003Cp>CBER 25-695592\u003C\u002Fp>\u003Cp>Dear Dr. Whitney:&nbsp;\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Finnatehealthcare.org (last visited August 2025), through which your company markets “umbilical cord mesenchymal stem cells (UC-MSCs),” which you also describe as “UC-MSC therapy” (hereinafter, “your product”) for allogeneic use. This letter is to advise you that your misbranding of your product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 331(k).&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, https:\u002F\u002Finnatehealthcare.org (last visited August 2025), your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,&nbsp;\u003C\u002Fp>\u003Cp>On your website, https:\u002F\u002Finnatehealthcare.org, you provide the following statements:\u003C\u002Fp>\u003Cul>\u003Cli>“At Innate Healthcare Institute, we combine an effective blend of integrative medicine and regenerative stem cell medicine, treating Autism at its root.”\u003C\u002Fli>\u003Cli>“Stem cell therapy has really helped our son with his autism”\u003C\u002Fli>\u003Cli>“Stem cell therapy with human umbilical cord tissue derived mesenchymal stem cells (UC-MSCs) corrects the inflammatory process by modulating the immune system from a pro-inflammatory attacking state to an anti-inflammatory healthy state. They also have the ability to regenerate damage done from the autoimmune attack. Stem cells do this by secreting healing activators such as growth factors, cytokines, and exosomes to the surrounding environment.”\u003C\u002Fli>\u003Cli>“Stem cell therapy for autism can lead to improvement in cognitive ability, behaviors, and sociability.”\u003C\u002Fli>\u003Cli>“Regenerative cell medicine has the potential to help with many conditions such as pain due to osteoarthritis, tendinopathy\u002Ftendonitis, degenerative disc disease, herniated discs, neuropathy, fractures, muscle injuries, ligament and tendon injuries, COPD, peripheral neuropathy, sexual dysfunction, autoimmune conditions, heart disease, and many more.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your product is a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).&nbsp;\u003C\u002Fp>\u003Cp>Your UC-MSCs product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Innate Healthcare Institute does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).&nbsp;\u003C\u002Fp>\u003Cp>For example, your UC-MSCs product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.&nbsp;\u003C\u002Fp>\u003Cp>In addition, your UC-MSCs product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your product is intended for use in the treatment of autism as well as other diseases or conditions, which is not a basic function of the umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>Furthermore, your product is a misbranded drug under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). Misbranding your product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act and biological products under section 351 of the PHS Act and and are subject to premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>CC:\u003C\u002Fp>\u003Cp>Innate Healthcare, LLC\u003Cbr>4840 East Indian School Road\u003Cbr>Suite 104\u003Cbr>Phoenix, AZ 85018\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-695592\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nTravis Whitney, NMD, DAASCP, MSc, MSAc\n\nRecipient Title\n\nFounder and Chief Medical Officer\n\nInnate Healthcare Institute\n\n4835 East Cactus Road, Suite 140\n\nScottsdale, AZ 85254\n\nUnited States\n\ninfo@innatehealthcare.org\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nAugust 15, 202\nCBER 25-695592\nDear Dr. Whitney:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Finnatehealthcare.org (last visited August 2025), through which your company markets “umbilical cord mesenchymal stem cells (UC-MSCs),” which you also describe as “UC-MSC therapy” (hereinafter, “your product”) for allogeneic use. This letter is to advise you that your misbranding of your product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(k).\nViolations\nBased on information and records reviewed by FDA, https:\u002F\u002Finnatehealthcare.org (last visited August 2025), your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nOn your website, https:\u002F\u002Finnatehealthcare.org, you provide the following statements:\n“At Innate Healthcare Institute, we combine an effective blend of integrative medicine and regenerative stem cell medicine, treating Autism at its root.”\n“Stem cell therapy has really helped our son with his autism”\n“Stem cell therapy with human umbilical cord tissue derived mesenchymal stem cells (UC-MSCs) corrects the inflammatory process by modulating the immune system from a pro-inflammatory attacking state to an anti-inflammatory healthy state. They also have the ability to regenerate damage done from the autoimmune attack. Stem cells do this by secreting healing activators such as growth factors, cytokines, and exosomes to the surrounding environment.”\n“Stem cell therapy for autism can lead to improvement in cognitive ability, behaviors, and sociability.”\n“Regenerative cell medicine has the potential to help with many conditions such as pain due to osteoarthritis, tendinopathy\u002Ftendonitis, degenerative disc disease, herniated discs, neuropathy, fractures, muscle injuries, ligament and tendon injuries, COPD, peripheral neuropathy, sexual dysfunction, autoimmune conditions, heart disease, and many more.”\nTherefore, your product is a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour UC-MSCs product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Innate Healthcare Institute does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\nFor example, your UC-MSCs product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your UC-MSCs product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your product is intended for use in the treatment of autism as well as other diseases or conditions, which is not a basic function of the umbilical cord in the donor.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\nFurthermore, your product is a misbranded drug under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). Misbranding your product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nAdditional Concerns\nFDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are regulated as drugs as defined in section 201(g)(1) of the FD&C Act and biological products under section 351 of the PHS Act and and are subject to premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCC:\nInnate Healthcare, LLC\n4840 East Indian School Road\nSuite 104\nPhoenix, AZ 85018\n____________________\n1 Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Innate Healthcare Institute","innate-healthcare-institute-695592-08152025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnate-healthcare-institute-695592-08152025","2026-10-26T08:08:58.9915+00:00","2025-08-26","695592","Biologics","Travis Whitney, NMD, DAASCP, MSc, MSAc","2026-08-19T16:28:46.246+00:00","VIA UPS and Electronic Mail","CBER 25-695592","2025-08-15",{"id":137,"raw":138,"subject":39,"body_html":141,"body_text":142,"firm_name":143,"letter_id":144,"created_at":44,"fei_number":19,"letter_url":145,"updated_at":146,"action_type":22,"case_status":23,"posted_date":147,"marcs_cms_no":148,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":149,"body_fetched_at":150,"delivery_method":51,"recipient_title":19,"reference_number":151,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},802,[139,36,140,11,39,13,13,13],"\u003Ctime datetime=\"2025-07-01T04:00:00Z\">07\u002F01\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealwell-homeo-private-limited-706206-06122025\">Healwell Homeo Private Limited \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-80\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Luv Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Healwell Homeo Private Limited \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot No. 215\u002F1 220\u002F1 &amp; 221\u002F1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Village Indrad, Tal Kadi, District Mehsana\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382170\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-80\u003C\u002Fp>\u003Cp>June 12, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Luv Patel:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Healwell Homeo Private Limited, FEI 3028192440, Plot No. 215\u002F1 220\u002F1 &amp; 221\u002F1, Village Indrad, Tal Kadi, District Mehsana, Ahmedabad, Gujarat, from December 13 to 20, 2024.\u003C\u002Fp>\u003Cp>Your drug products are adulterated under section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), in that they have been prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health.\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>As of the date of this letter, you have not responded to the Form FDA 483 inspectional observations, despite two inquiries from the Agency regarding your intent to do so. After FDA detained a shipment of drugs manufactured at your facility at the border on March 19, 2025, you sent an email, dated March 26, 2025, requesting a 90-day extension to respond to the Form FDA 483.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Insanitary Conditions\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures homeopathic and over-the-counter (OTC) drug products. Your drug products are adulterated under section 501(a)(2)(A) of the FD&amp;C Act because they were prepared, packed, and held under insanitary conditions. Specifically, our investigator observed evidence of both rodent and avian activity, including the presence of live rodents and birds, as well as extensive rodent and avian excreta in areas where container-closure systems and finished drug products are stored. Further, the investigator observed the following:\u003C\u002Fp>\u003Cul>\u003Cli>Apparent rodent excreta pellets throughout the finished product storage area, as well as areas containing drug packaging and packaging containers (boxes and uncapped \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials).\u003C\u002Fli>\u003Cli>Birds living in storage areas, bird droppings and feathers on walls, floors, and throughout the packaging and labeling materials storage area.\u003C\u002Fli>\u003Cli>Unknown black mold-like material on the ceiling above manufacturing equipment and on the wall adjacent to open \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks and filling lines.\u003C\u002Fli>\u003Cli>Insects in manufacturing areas.\u003C\u002Fli>\u003Cli>Stray dogs loitering near open entryways with soiled \u003Cstrong>(b)(4)\u003C\u002Fstrong> serving as the only barrier to entry.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> used in manufacturing was stored outdoors in dirty drums.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive plan to decontaminate the facility, given the pervasive nature of the insanitary conditions.\u003C\u002Fli>\u003Cli>Your corrective action and preventive action plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>Detailed procedures that demonstrate your firm can maintain buildings free from pests and that they remain in a clean and sanitary state.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component suppliers’ test analyses at appropriate intervals (21 CFR 211.84(d)(1)) and 211.84(d)(2).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test samples of your incoming components before using them to manufacture your homeopathic and OTC drug products. During the inspection, you informed the investigator that you reviewed certificates of analysis (COAs) for incoming materials, but did not perform identity testing, did not verify the supplier COA, and did not have a quarantine or approval process.\u003C\u002Fp>\u003Cp>Furthermore, you used \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a component in some of your drug products. Our investigator documented that you received \u003Cstrong>(b)(4)\u003C\u002Fstrong> from your supplier in \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums that bear the label \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated that you did not test this \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to use in production. It is unacceptable to not conduct identity testing on a drug competent, especially knowing it is labeled as another component.\u003C\u002Fp>\u003Cp>At a minimum, you must use \u003Cstrong>(b)(4)\u003C\u002Fstrong> (refer to USP General Chapter \u003Cstrong>(b)(4)\u003C\u002Fstrong>) to manufacture your non-sterile drug products. \u003Cstrong>(b)(4)\u003C\u002Fstrong> must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. You have not demonstrated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is suitable for use and meets the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>Provide scientific justification to demonstrate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you use is suitable for use in drug manufacturing operations. If you determine the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you used to manufacture drugs was not suitable, provide a detailed risk assessment addressing the potential effects on the quality of all drug product lots currently in U.S. distribution and within expiry. Specify actions you will take in response to the risk assessment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, our investigator observed that your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of written procedures for numerous functions including, but not limited to, complaints, deviations, investigations, cleaning and maintenance of equipment, employee training, and labeling operations (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Adequate validation of production and process controls used in the manufacture of your drug products, including qualification of the equipment used in drug manufacturing (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\u003C\u002Fli>\u003Cli>Adequate written procedures for test methods and sampling plans (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>Adequate cleaning procedures as well as appropriate cleaning validation (21 CFR 211.67(a) and 211.67(b)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process\u003Cbr>Healwell Homeo Private Limited, Ahmedabad FEI 3028192440 page 5\u003Cbr>performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>After the inspection, FDA made multiple unsuccessful attempts to schedule a teleconference with you to recommend removing your drug products from the U.S. market. On April 2, 2025, FDA held a call with your distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to provide notice of the conditions at your facility and recommend market action. On April 8, 2025, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a recall of products manufactured at your facility, currently in U.S. distribution.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on March 31, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Healwell Homeo Private Limited, FEI 3028192440, Plot No. 215\u002F1 220\u002F1 &amp; 221\u002F1, Village Indrad, Tal Kadi, District Mehsana, Ahmedabad, Gujarat, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3028192440 and ATTN: Rokshana Safaai-Jazi.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-80\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Luv Patel\n\nRecipient Title\n\nOwner\n\nHealwell Homeo Private Limited\n\nPlot No. 215\u002F1 220\u002F1 & 221\u002F1\n\nVillage Indrad, Tal Kadi, District Mehsana\n\nAhmedabad 382170\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-80\nJune 12, 2025\nDear Mr. Luv Patel:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Healwell Homeo Private Limited, FEI 3028192440, Plot No. 215\u002F1 220\u002F1 & 221\u002F1, Village Indrad, Tal Kadi, District Mehsana, Ahmedabad, Gujarat, from December 13 to 20, 2024.\nYour drug products are adulterated under section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), in that they have been prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health.\nThis warning letter also summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nAs of the date of this letter, you have not responded to the Form FDA 483 inspectional observations, despite two inquiries from the Agency regarding your intent to do so. After FDA detained a shipment of drugs manufactured at your facility at the border on March 19, 2025, you sent an email, dated March 26, 2025, requesting a 90-day extension to respond to the Form FDA 483.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\nInsanitary Conditions\nYour firm manufactures homeopathic and over-the-counter (OTC) drug products. Your drug products are adulterated under section 501(a)(2)(A) of the FD&C Act because they were prepared, packed, and held under insanitary conditions. Specifically, our investigator observed evidence of both rodent and avian activity, including the presence of live rodents and birds, as well as extensive rodent and avian excreta in areas where container-closure systems and finished drug products are stored. Further, the investigator observed the following:\nApparent rodent excreta pellets throughout the finished product storage area, as well as areas containing drug packaging and packaging containers (boxes and uncapped (b)(4) vials).\nBirds living in storage areas, bird droppings and feathers on walls, floors, and throughout the packaging and labeling materials storage area.\nUnknown black mold-like material on the ceiling above manufacturing equipment and on the wall adjacent to open (b)(4) tanks and filling lines.\nInsects in manufacturing areas.\nStray dogs loitering near open entryways with soiled (b)(4) serving as the only barrier to entry.\n(b)(4) used in manufacturing was stored outdoors in dirty drums.\nIn response to this letter, provide:\nA comprehensive plan to decontaminate the facility, given the pervasive nature of the insanitary conditions.\nYour corrective action and preventive action plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nDetailed procedures that demonstrate your firm can maintain buildings free from pests and that they remain in a clean and sanitary state.\nCGMP Violations\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component suppliers’ test analyses at appropriate intervals (21 CFR 211.84(d)(1)) and 211.84(d)(2).\nYou failed to adequately test samples of your incoming components before using them to manufacture your homeopathic and OTC drug products. During the inspection, you informed the investigator that you reviewed certificates of analysis (COAs) for incoming materials, but did not perform identity testing, did not verify the supplier COA, and did not have a quarantine or approval process.\nFurthermore, you used (b)(4) as a component in some of your drug products. Our investigator documented that you received (b)(4) from your supplier in (b)(4) drums that bear the label (b)(4). You stated that you did not test this (b)(4) prior to use in production. It is unacceptable to not conduct identity testing on a drug competent, especially knowing it is labeled as another component.\nAt a minimum, you must use (b)(4) (refer to USP General Chapter (b)(4)) to manufacture your non-sterile drug products. (b)(4) must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. You have not demonstrated that the (b)(4) is suitable for use and meets the USP (b)(4) monograph.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\nIn response to this letter, provide:\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nProvide scientific justification to demonstrate the (b)(4) you use is suitable for use in drug manufacturing operations. If you determine the (b)(4) you used to manufacture drugs was not suitable, provide a detailed risk assessment addressing the potential effects on the quality of all drug product lots currently in U.S. distribution and within expiry. Specify actions you will take in response to the risk assessment.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nDuring the inspection, our investigator observed that your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\nEstablishment of written procedures for numerous functions including, but not limited to, complaints, deviations, investigations, cleaning and maintenance of equipment, employee training, and labeling operations (21 CFR 211.22(d)).\nAdequate validation of production and process controls used in the manufacture of your drug products, including qualification of the equipment used in drug manufacturing (21 CFR 211.100(a)).\nAppropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\nAdequate written procedures for test methods and sampling plans (21 CFR 211.160(b)).\nAdequate cleaning procedures as well as appropriate cleaning validation (21 CFR 211.67(a) and 211.67(b)).\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\nIn response to this letter, provide the following:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process\nHealwell Homeo Private Limited, Ahmedabad FEI 3028192440 page 5\nperformance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ for each of your marketed drug products.\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nDrug Recall\nAfter the inspection, FDA made multiple unsuccessful attempts to schedule a teleconference with you to recommend removing your drug products from the U.S. market. On April 2, 2025, FDA held a call with your distributor, (b)(4), to provide notice of the conditions at your facility and recommend market action. On April 8, 2025, (b)(4), initiated a recall of products manufactured at your facility, currently in U.S. distribution.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on March 31, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Healwell Homeo Private Limited, FEI 3028192440, Plot No. 215\u002F1 220\u002F1 & 221\u002F1, Village Indrad, Tal Kadi, District Mehsana, Ahmedabad, Gujarat, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3028192440 and ATTN: Rokshana Safaai-Jazi.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Healwell Homeo Private Limited","healwell-homeo-private-limited-706206-06122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealwell-homeo-private-limited-706206-06122025","2026-10-26T08:08:54.027272+00:00","2025-07-01","706206","Mr. Luv Patel","2026-08-19T16:38:06.767+00:00","320-25-80",{"id":153,"raw":154,"subject":39,"body_html":158,"body_text":159,"firm_name":160,"letter_id":161,"created_at":66,"fei_number":19,"letter_url":162,"updated_at":163,"action_type":22,"case_status":23,"posted_date":164,"marcs_cms_no":165,"product_type":26,"closeout_date":19,"issuing_office":60,"recipient_name":166,"body_fetched_at":167,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":168,"medical_device_id":19,"response_letter_date":19},1966,[155,156,157,60,39,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-25T04:00:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-healthcare-corporation-654136-07252023\">Baxter Healthcare Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. José E. Almeida\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman, CEO and President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Baxter Healthcare Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Baxter Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Deerfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-18\u003C\u002Fp>\n\n\u003Cp>July 25, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Almeida:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, India, from January 19 to January 27, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 17, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to conduct adequate investigations into endotoxin testing and your 100% automated visual inspection system. You conducted investigations that were not thorough, expanded to an appropriate scope, or based on scientifically supported root cause(s). You did not identify and implement appropriate corrective actions and preventive actions (CAPA). Specifically,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm invalidated multiple endotoxin tests for finished products upon discovery of particulate matter in one or more wells used to perform the kinetic-turbidimetric assay (KTA) method. You failed to characterize the particulate matter and attributed the particulates to environmental and laboratory conditions, such as air ducts and activities being performed by personnel in the immediate vicinity of the analysis. You did not definitively identify the source or sources of the particulate matter, define the scope of potentially impacted operations (including potential manufacturing causes), and implement scientifically justified CAPA in a timely manner.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In a previous inspection (May 2022), FDA cited your firm for inadequate investigations into these and other similar out-of-specification (OOS) endotoxin testing that you invalidated due to uncharacterized particulate contamination in one or more wells during KTA analyses. Prior to and during an October 5, 2022 regulatory meeting with your firm, we requested you perform a retrospective assessment of investigations associated with OOS endotoxin results or endotoxin testing deviations. During the current inspection, your personnel explained that these investigations were not reopened or otherwise reassessed. Although you retained a third-party consultant to perform a retrospective assessment of endotoxin investigations associated with OOS endotoxin result investigations, you did not provide the third-party consultant with an investigation cited during the May 2022 inspection. You also did not ensure the assessment included approximately 20 invalidated laboratory tests generated in 2021 and 2022 (including multiple investigations since the May 2022 inspection).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm did not adequately investigate failures of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine to detect known defects, including particulate matter in injectable drug products. Despite the data indicating significant deficiencies in the machine’s ability to detect known defects during its use, you continued to employ the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine to inspect commercially distributed products (e.g., several batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL USP). Notably, you fully relied on this automated visual inspection system to detect various defects including particulate contamination for an extended period and did not perform a 100% manual visual inspection for all defects.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Challenges with defect kits indicated failing rejection rates or other deficiencies. For example, an October 2022 challenge excluded the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles despite their lower detectability than other “dark” particles in \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL amber glass vials. The challenge also used a highly detectable particle range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> μm, but still indicated detection and capability issues. Similar challenges to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine utilized commercial inspection parameters. You did not initiate adequate investigations into these detection issues. You lacked adequate assurance that sterile injectable drug batches visually inspected with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine were free from visible particulates.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your firm previously committed to evaluate and implement improvements to your procedures and practices associated with the conduct of investigations following the conclusion of the July 27 to August 4, 2017, inspection of this facility and in response to the warning letter sent to your firm on July 5, 2018. You also reported significant CAPA activities to address the frequency of endotoxin testing OOS results and deviations following the October 5, 2022, regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>In your February 17, 2023, response to the Form FDA 483 issued at the conclusion of the most recent inspection, you commit to further revisions of your investigation procedures.\u003C\u002Fp>\n\n\u003Cp>However, you do not adequately address your failure to conduct timely investigations into recurring and persistent issues. Your response did not adequately address the use of insufficiently qualified \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment for 100% visual inspection of injectable drug products for approximately five years (until October 2022) and the excessive number of samples contaminated with endotoxins or particles in your laboratory.\u003C\u002Fp>\n\n\u003Cp>We encourage the use of automated visual inspection for particulates to augment the 100% manual visual inspection program. Automated methods should be rigorously studied for their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, and other variables. In addition, any use of automated particulate inspection does not supplant the need for 100% manual visual inspection for various other attributes (e.g., cracks).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A written commitment to have all lots of finished products manufactured at your facility analyzed for endotoxins by a qualified laboratory until you have thoroughly investigated each endotoxin test invalidation event since January 1, 2018, and implemented all necessary CAPA to prevent recurrence of endotoxin result invalidations. This should include but not be limited to assuring CAPA effectiveness for your particulate and pipetting issues.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter, used for products distributed in the United States that remain within expiry. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness.\u003C\u002Fli>\n\t\u003Cli>An independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A third-party protocol and the executed protocol final report for the retrospective review of particulate matter investigations associated with distributed in the United States that remain within expiry, irrespective of whether the original investigation resulted in the invalidation of the original result. The protocol should include an evaluation of the investigation’s thoroughness; assignment and scientific justification for root cause(s); documentation of CAPA implementation, and documented effectiveness of CAPA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>An FDA investigator observed white spots at the bottom of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> L bulk solution holding tank used to supply a non-dedicated filling machine despite the vessel being documented as clean. You subsequently analyzed and identified the white spots as \u003Cstrong>(b)(4)\u003C\u002Fstrong> (the product previously processed on this equipment) at levels of up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> parts per million (ppm). Your limit for post-cleaning residues is not more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you revised your cleaning procedure to require vessels to be dry before conducting the visual inspection for cleanliness and implemented visual verification of the vessel interior via a sight glass following the cleaning and \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities, you did not provide scientific justification for your use of visual inspection to verify the removal of residues to levels as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Your response noted \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, not \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, is the “worst-case product” processed in this vessel, but you did not provide a comprehensive investigation to assess the impact of this cleaning deviation on products previously manufactured on this and other non-dedicated equipment. You also did not propose a systemic assessment of your equipment cleaning program.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your program for the visual inspection of sterile injectable drug products does not provide adequate assurance that finished products manufactured at your facility possess their purported quality attributes, including that they are free from particulate matter. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Personnel performed 100% manual visual inspection of sterile injectable units for less than the minimum amount of time required by your written procedures.\u003C\u002Fli>\n\t\u003Cli>You lacked scientific justification for removing vials containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles from the defect kits used to qualify visual inspection processes. For example, although \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles were more difficult to reproducibly detect than \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper particles in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL amber vials, you elected to only use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper particles in the defect kits.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate. You commit to using a “pacing device” during the 100% manual visual inspections and requiring a supervisor to periodically verify the inspection times. You did not provide a description of the pacing device or commit to requalify operators following implementation of the pacing device. Additionally, you did not commit to evaluate operator performance throughout a \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You also state a successful qualification program does not evaluate “… an inspector’s ability to differentiate and identify various types and morphologies of particles.” However, it is critical to be able to reproducibly detect particulate defects of different types, morphologies, and sizes.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility to the United States that remains within expiry to meet the requirement of being essentially free of visible particles. The assessment should also include consideration of gaps and other deficiencies identified in the independent assessment of your systems for visual inspection of sterile injectable drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Equipment used in the manufacture of terminally sterilized drugs at your facility is not designed or maintained appropriately. Our inspection revealed instances of damaged metal and plastic parts, open vials exposed to worn bolt threading, and process flow that required employees to duck underneath the sterile processing line conveyer in order to perform interventions near open vials (e.g., stopper addition on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line).\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you commit to replacing the threaded bolt \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line with a different part that will not expose a threading over open vials, you did not commit to evaluate production rooms and production equipment for wear, damage, or poor design that may lead to the generation of particulate matter in the vicinity of open vials. You also plan to install a \u003Cstrong>(b)(4)\u003C\u002Fstrong> conveyor at the capping machine outfeed, and merge filling and capping areas, for two filling lines (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), but you did not commit to perform a comprehensive assessment of your facility’s production lines to ensure they are appropriately designed and controlled.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of the design of each sterile drug production line, including facility layout, equipment placement and ergonomics, and personnel and material flow. Provide your detailed remediation plan with timelines to address the findings of the assessment. Describe specific tangible improvements to be made to the sterile processing operation design and control. Include a plan to assess the effectiveness of the improvements.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the condition of equipment including change parts, and the procedures and practices associated with equipment maintenance. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and periodic assessment of the plan’s effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Process Controls\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FProcess-Validation--General-Principles-and-Practices.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 and independent of your firm to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004610460 and ATTN: Jason F. Chancey.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc: Rishikesh Jaiwant, Senior Director Manufacturing and Operations- Ahmedabad\u003Cbr>\n(rishikesh_jaiwant@baxter.com)\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. José E. Almeida\n\nRecipient Title\n\nChairman, CEO and President\n\nBaxter Healthcare Corporation\n\n1 Baxter Parkway\n\nDeerfield, IL 60015\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-18\n\nJuly 25, 2023\n\nDear Mr. Almeida:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, India, from January 19 to January 27, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 17, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to conduct adequate investigations into endotoxin testing and your 100% automated visual inspection system. You conducted investigations that were not thorough, expanded to an appropriate scope, or based on scientifically supported root cause(s). You did not identify and implement appropriate corrective actions and preventive actions (CAPA). Specifically,\n\nYour firm invalidated multiple endotoxin tests for finished products upon discovery of particulate matter in one or more wells used to perform the kinetic-turbidimetric assay (KTA) method. You failed to characterize the particulate matter and attributed the particulates to environmental and laboratory conditions, such as air ducts and activities being performed by personnel in the immediate vicinity of the analysis. You did not definitively identify the source or sources of the particulate matter, define the scope of potentially impacted operations (including potential manufacturing causes), and implement scientifically justified CAPA in a timely manner.\n\nIn a previous inspection (May 2022), FDA cited your firm for inadequate investigations into these and other similar out-of-specification (OOS) endotoxin testing that you invalidated due to uncharacterized particulate contamination in one or more wells during KTA analyses. Prior to and during an October 5, 2022 regulatory meeting with your firm, we requested you perform a retrospective assessment of investigations associated with OOS endotoxin results or endotoxin testing deviations. During the current inspection, your personnel explained that these investigations were not reopened or otherwise reassessed. Although you retained a third-party consultant to perform a retrospective assessment of endotoxin investigations associated with OOS endotoxin result investigations, you did not provide the third-party consultant with an investigation cited during the May 2022 inspection. You also did not ensure the assessment included approximately 20 invalidated laboratory tests generated in 2021 and 2022 (including multiple investigations since the May 2022 inspection).\n\nYour firm did not adequately investigate failures of the (b)(4) automatic inspection machine to detect known defects, including particulate matter in injectable drug products. Despite the data indicating significant deficiencies in the machine’s ability to detect known defects during its use, you continued to employ the (b)(4) automatic inspection machine to inspect commercially distributed products (e.g., several batches of (b)(4) injection (b)(4) mg\u002FmL USP). Notably, you fully relied on this automated visual inspection system to detect various defects including particulate contamination for an extended period and did not perform a 100% manual visual inspection for all defects.\n\nChallenges with defect kits indicated failing rejection rates or other deficiencies. For example, an October 2022 challenge excluded the use of (b)(4) particles despite their lower detectability than other “dark” particles in (b)(4) mL amber glass vials. The challenge also used a highly detectable particle range of (b)(4) μm, but still indicated detection and capability issues. Similar challenges to the (b)(4) automatic inspection machine utilized commercial inspection parameters. You did not initiate adequate investigations into these detection issues. You lacked adequate assurance that sterile injectable drug batches visually inspected with the (b)(4) automatic inspection machine were free from visible particulates.\n\nYour response is inadequate. Your firm previously committed to evaluate and implement improvements to your procedures and practices associated with the conduct of investigations following the conclusion of the July 27 to August 4, 2017, inspection of this facility and in response to the warning letter sent to your firm on July 5, 2018. You also reported significant CAPA activities to address the frequency of endotoxin testing OOS results and deviations following the October 5, 2022, regulatory meeting.\n\nIn your February 17, 2023, response to the Form FDA 483 issued at the conclusion of the most recent inspection, you commit to further revisions of your investigation procedures.\n\nHowever, you do not adequately address your failure to conduct timely investigations into recurring and persistent issues. Your response did not adequately address the use of insufficiently qualified (b)(4) equipment for 100% visual inspection of injectable drug products for approximately five years (until October 2022) and the excessive number of samples contaminated with endotoxins or particles in your laboratory.\n\nWe encourage the use of automated visual inspection for particulates to augment the 100% manual visual inspection program. Automated methods should be rigorously studied for their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, and other variables. In addition, any use of automated particulate inspection does not supplant the need for 100% manual visual inspection for various other attributes (e.g., cracks).\n\nIn response to this letter, provide:\n\nA written commitment to have all lots of finished products manufactured at your facility analyzed for endotoxins by a qualified laboratory until you have thoroughly investigated each endotoxin test invalidation event since January 1, 2018, and implemented all necessary CAPA to prevent recurrence of endotoxin result invalidations. This should include but not be limited to assuring CAPA effectiveness for your particulate and pipetting issues.\n\nA comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter, used for products distributed in the United States that remain within expiry. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness.\n\nAn independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n\nA third-party protocol and the executed protocol final report for the retrospective review of particulate matter investigations associated with distributed in the United States that remain within expiry, irrespective of whether the original investigation resulted in the invalidation of the original result. The protocol should include an evaluation of the investigation’s thoroughness; assignment and scientific justification for root cause(s); documentation of CAPA implementation, and documented effectiveness of CAPA.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nAn FDA investigator observed white spots at the bottom of a (b)(4) L bulk solution holding tank used to supply a non-dedicated filling machine despite the vessel being documented as clean. You subsequently analyzed and identified the white spots as (b)(4) (the product previously processed on this equipment) at levels of up to (b)(4) parts per million (ppm). Your limit for post-cleaning residues is not more than (b)(4) ppm.\n\nYour response is inadequate. Although you revised your cleaning procedure to require vessels to be dry before conducting the visual inspection for cleanliness and implemented visual verification of the vessel interior via a sight glass following the cleaning and (b)(4) activities, you did not provide scientific justification for your use of visual inspection to verify the removal of residues to levels as low as (b)(4) ppm. Your response noted (b)(4) injection, not (b)(4) injection, is the “worst-case product” processed in this vessel, but you did not provide a comprehensive investigation to assess the impact of this cleaning deviation on products previously manufactured on this and other non-dedicated equipment. You also did not propose a systemic assessment of your equipment cleaning program.\n\nIn response to this letter, provide:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\n\nYour program for the visual inspection of sterile injectable drug products does not provide adequate assurance that finished products manufactured at your facility possess their purported quality attributes, including that they are free from particulate matter. For example,\n\nPersonnel performed 100% manual visual inspection of sterile injectable units for less than the minimum amount of time required by your written procedures.\n\nYou lacked scientific justification for removing vials containing (b)(4) particles from the defect kits used to qualify visual inspection processes. For example, although (b)(4) particles were more difficult to reproducibly detect than (b)(4) stopper particles in the (b)(4) mL amber vials, you elected to only use the (b)(4) stopper particles in the defect kits.\n\nYour response is inadequate. You commit to using a “pacing device” during the 100% manual visual inspections and requiring a supervisor to periodically verify the inspection times. You did not provide a description of the pacing device or commit to requalify operators following implementation of the pacing device. Additionally, you did not commit to evaluate operator performance throughout a (b)(4).\n\nYou also state a successful qualification program does not evaluate “… an inspector’s ability to differentiate and identify various types and morphologies of particles.” However, it is critical to be able to reproducibly detect particulate defects of different types, morphologies, and sizes.\n\nIn response to this letter, provide a comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility to the United States that remains within expiry to meet the requirement of being essentially free of visible particles. The assessment should also include consideration of gaps and other deficiencies identified in the independent assessment of your systems for visual inspection of sterile injectable drugs.\n\n4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\n\nEquipment used in the manufacture of terminally sterilized drugs at your facility is not designed or maintained appropriately. Our inspection revealed instances of damaged metal and plastic parts, open vials exposed to worn bolt threading, and process flow that required employees to duck underneath the sterile processing line conveyer in order to perform interventions near open vials (e.g., stopper addition on the (b)(4) filling line).\n\nYour response is inadequate. Although you commit to replacing the threaded bolt (b)(4) on the (b)(4) filling line with a different part that will not expose a threading over open vials, you did not commit to evaluate production rooms and production equipment for wear, damage, or poor design that may lead to the generation of particulate matter in the vicinity of open vials. You also plan to install a (b)(4) conveyor at the capping machine outfeed, and merge filling and capping areas, for two filling lines ((b)(4) and (b)(4)), but you did not commit to perform a comprehensive assessment of your facility’s production lines to ensure they are appropriately designed and controlled.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of the design of each sterile drug production line, including facility layout, equipment placement and ergonomics, and personnel and material flow. Provide your detailed remediation plan with timelines to address the findings of the assessment. Describe specific tangible improvements to be made to the sterile processing operation design and control. Include a plan to assess the effectiveness of the improvements.\n\nA comprehensive, independent assessment of the condition of equipment including change parts, and the procedures and practices associated with equipment maintenance. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and periodic assessment of the plan’s effectiveness.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nProcess Controls\n\nYour firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FProcess-Validation--General-Principles-and-Practices.pdf.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 and independent of your firm to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nWe request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004610460 and ATTN: Jason F. Chancey.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCc: Rishikesh Jaiwant, Senior Director Manufacturing and Operations- Ahmedabad\n\n(rishikesh_jaiwant@baxter.com)\n\n_________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Baxter Healthcare Corporation","baxter-healthcare-corporation-654136-07252023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-healthcare-corporation-654136-07252023","2026-10-26T08:08:01.800292+00:00","2023-08-01","654136","Mr. José E. Almeida","2026-08-20T00:49:44.234+00:00","2023-07-25",{"id":170,"raw":171,"subject":175,"body_html":176,"body_text":177,"firm_name":178,"letter_id":179,"created_at":180,"fei_number":19,"letter_url":181,"updated_at":182,"action_type":22,"case_status":23,"posted_date":183,"marcs_cms_no":184,"product_type":185,"closeout_date":19,"issuing_office":11,"recipient_name":186,"body_fetched_at":187,"delivery_method":188,"recipient_title":19,"reference_number":19,"action_taken_date":189,"medical_device_id":19,"response_letter_date":19},21685,[172,173,174,11,175,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-01T04:00:00Z\">10\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-healthcare-llc-735147-10012026\">The Platinum Healthcare LLC\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jamey Hagan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Platinum Healthcare LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1019 N 1st Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pulaski\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38478\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:office@platinumwellnesscenter.org\"> office@platinumwellnesscenter.org\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 735147\u003C\u002Fp>\u003Cp>To Jamey Hagan:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fplatinumwellnesscenter.org\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, the “Sycosis” and “Syphillinum” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Fplatinumwellnesscenter.org\u002F in July 2026. Based on our review, “Sycosis” and “Syphillinum” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “Sycosis” and “Syphillinum” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Sycosis\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fplatinumwellnesscenter.org\u002Fstore\u002Fsycosis\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Gonorrhea miasm.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Syphillinum\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fplatinumwellnesscenter.org\u002Fstore\u002Fsyphilinum\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Syphilis miasm.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“Sycosis” and “Syphillinum” are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We recognize that your “Sycosis” and “Syphillinum” products are labeled as homeopathic drugs with active ingredient(s) measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735147” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJamey Hagan\n\nRecipient Title\n\nCEO\n\nThe Platinum Healthcare LLC\n\n1019 N 1st Street\n\nPulaski, TN 38478\n\nUnited States\n\noffice@platinumwellnesscenter.org\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 1, 2026\nWARNING LETTER\nReference Number: 735147\nTo Jamey Hagan:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fplatinumwellnesscenter.org\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, the “Sycosis” and “Syphillinum” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Fplatinumwellnesscenter.org\u002F in July 2026. Based on our review, “Sycosis” and “Syphillinum” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “Sycosis” and “Syphillinum” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nSycosis\nOn the webpage https:\u002F\u002Fplatinumwellnesscenter.org\u002Fstore\u002Fsycosis\u002F:\n“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Gonorrhea miasm.”\nSyphillinum\nOn the webpage https:\u002F\u002Fplatinumwellnesscenter.org\u002Fstore\u002Fsyphilinum\u002F:\n“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Syphilis miasm.”\n“Sycosis” and “Syphillinum” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe recognize that your “Sycosis” and “Syphillinum” products are labeled as homeopathic drugs with active ingredient(s) measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735147” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","The Platinum Healthcare LLC","platinum-healthcare-llc-735147-10012026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-healthcare-llc-735147-10012026","2026-11-17T01:02:03.701861+00:00","2026-10-06","735147","Drugs Over-the-Counter Drugs","Jamey Hagan","2026-10-14T12:33:33.251+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-01",{"id":191,"raw":192,"subject":39,"body_html":196,"body_text":197,"firm_name":198,"letter_id":199,"created_at":180,"fei_number":19,"letter_url":200,"updated_at":201,"action_type":22,"case_status":23,"posted_date":202,"marcs_cms_no":203,"product_type":185,"closeout_date":19,"issuing_office":11,"recipient_name":204,"body_fetched_at":205,"delivery_method":188,"recipient_title":19,"reference_number":206,"action_taken_date":207,"medical_device_id":19,"response_letter_date":19},21706,[193,194,195,11,39,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-21T04:00:00Z\">09\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbabikian-healthcare-products-cjsc-730513-09212026\">Babikian Healthcare Products CJSC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-128\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Dikran Babikian\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Babikian Healthcare Products CJSC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Gevorg Chaush Highway 90\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>2413\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Proshyan Community\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kotayk\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Armenia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 21, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-128\u003C\u002Fp>\u003Cp>To Dr. Dikran Babikian:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, Babikian Healthcare Products CJSC, FDA Establishment Identifier (FEI) 3027526825.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 12, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) &amp; 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, intended for the U.S. market. Your response to our request for records and information under section 704(a)(4) indicated that you do not test the identity of each incoming component, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your drug products prior to manufacturing. Your response also indicated that you accept your suppliers’ certificates of analyses without verifying the test results at appropriate intervals.\u003C\u002Fp>\u003Cp>You also did not provide evidence that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the active ingredients in your drug products, meet USP limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\">.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Without adequate testing and verification of supplier results, you do not have scientific evidence that your incoming components conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you adequately test your finished OTC drug products prior to release and distribution to the United States. For example, the finished product testing reports you provided did not include appropriate assay testing for the identity and strength of each active ingredient or for impurities prior to release. Additionally, the records you provided failed to demonstrate adequate microbiological testing for each batch of your drug product prior to release.\u003C\u002Fp>\u003Cp>Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all predetermined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that your quality unit (QU) adequately exercised its authority and responsibilities for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishing appropriate written procedures for production and process controls to qualify process performance and for qualification of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, which produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> used as a component in your drug products (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Maintaining complete manufacturing information relating to the production and control in batch records (21 CFR 211.188).\u003C\u002Fli>\u003Cli>Providing appropriate stability data to support the labeled drug product expiration date (21 CFR 211.137(a)).\u003C\u002Fli>\u003Cli>Establishing adequate QU authority and procedures (21 CFR 211.22(a) &amp; 211.22(d)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA guidance documents \u003Cem>Quality Systems Approach to Pharmaceuticals CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Registration and Listing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We note that two separate establishments are referenced in this warning letter. Under section 510(i) of the FD&amp;C Act and 21 CFR 207.17(a) any establishment within any foreign country engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States must be registered with FDA. Under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p), it is a prohibited act to fail to register an establishment as required by section 510 of the FD&amp;C Act. Additionally, a drug may be considered misbranded within the meaning of section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o) if it was manufactured in an establishment not duly registered under section 510 of the FD&amp;C Act. It is your responsibility to ensure that all drugs manufactured at your establishment(s) comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firms, FEI 3027526825 and FEI 3032638909, on Import Alert 66-40 on June 22, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Babikian Healthcare Products CJSC, Gevorg Chaush Highway 90, Proshyan Community, Kotayk 2413 Armenia into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3027526825 and ATTN: Christina Capacci-Daniel in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>U.S. Agent: Mr. Michael Sarian\u003Cbr>American Healthcare Systems Corp., Inc.\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that Babikian Healthcare Products, 8 North Ave, Apartment 22, Yerevan, FEI 3032638909 was also listed as the manufacturer of record for several shipments to the U.S. but was not a registered FDA manufacturing facility. See the Facility Registration section below for guidance.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-26-128\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nDr. Dikran Babikian\n\nRecipient Title\n\nChief Executive Officer\n\nBabikian Healthcare Products CJSC\n\nGevorg Chaush Highway 90\n\n2413\n\nProshyan Community\n\nKotayk\n\nArmenia\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 21, 2026\nWARNING LETTER\nReference number: 320-26-128\nTo Dr. Dikran Babikian:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, Babikian Healthcare Products CJSC, FDA Establishment Identifier (FEI) 3027526825.1 This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 12, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) & 211.84(d)(2)).\nYour firm manufactures OTC drug products, including (b)(4), intended for the U.S. market. Your response to our request for records and information under section 704(a)(4) indicated that you do not test the identity of each incoming component, (b)(4), used in the manufacture of your drug products prior to manufacturing. Your response also indicated that you accept your suppliers’ certificates of analyses without verifying the test results at appropriate intervals.\nYou also did not provide evidence that (b)(4), the active ingredients in your drug products, meet USP limits for (b)(4). See FDA’s guidance document (b)(4).\nWithout adequate testing and verification of supplier results, you do not have scientific evidence that your incoming components conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nBased on the records and information you provided, you did not demonstrate that you adequately test your finished OTC drug products prior to release and distribution to the United States. For example, the finished product testing reports you provided did not include appropriate assay testing for the identity and strength of each active ingredient or for impurities prior to release. Additionally, the records you provided failed to demonstrate adequate microbiological testing for each batch of your drug product prior to release.\nTesting is an essential part of CGMP to ensure that the drug products you manufacture conform to all predetermined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nBased on the records and information you provided, you did not demonstrate that your quality unit (QU) adequately exercised its authority and responsibilities for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\nEstablishing appropriate written procedures for production and process controls to qualify process performance and for qualification of your (b)(4) system, which produces (b)(4) used as a component in your drug products (21 CFR 211.100(a)).\nMaintaining complete manufacturing information relating to the production and control in batch records (21 CFR 211.188).\nProviding appropriate stability data to support the labeled drug product expiration date (21 CFR 211.137(a)).\nEstablishing adequate QU authority and procedures (21 CFR 211.22(a) & 211.22(d)).\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA guidance documents Quality Systems Approach to Pharmaceuticals CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nDrug Registration and Listing\nWe note that two separate establishments are referenced in this warning letter. Under section 510(i) of the FD&C Act and 21 CFR 207.17(a) any establishment within any foreign country engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States must be registered with FDA. Under section 301(p) of the FD&C Act, 21 U.S.C. 331(p), it is a prohibited act to fail to register an establishment as required by section 510 of the FD&C Act. Additionally, a drug may be considered misbranded within the meaning of section 502(o) of the FD&C Act, 21 U.S.C. 352(o) if it was manufactured in an establishment not duly registered under section 510 of the FD&C Act. It is your responsibility to ensure that all drugs manufactured at your establishment(s) comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations.\nCGMP Consultant\nBased upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firms, FEI 3027526825 and FEI 3032638909, on Import Alert 66-40 on June 22, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Babikian Healthcare Products CJSC, Gevorg Chaush Highway 90, Proshyan Community, Kotayk 2413 Armenia into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3027526825 and ATTN: Christina Capacci-Daniel in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\ncc:\nU.S. Agent: Mr. Michael Sarian\nAmerican Healthcare Systems Corp., Inc.\n(b)(4)\n______________________________\n1 We note that Babikian Healthcare Products, 8 North Ave, Apartment 22, Yerevan, FEI 3032638909 was also listed as the manufacturer of record for several shipments to the U.S. but was not a registered FDA manufacturing facility. See the Facility Registration section below for guidance.","Babikian Healthcare Products CJSC","babikian-healthcare-products-cjsc-730513-09212026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbabikian-healthcare-products-cjsc-730513-09212026","2026-11-10T01:02:16.121874+00:00","2026-09-29","730513","Dr. Dikran Babikian","2026-10-14T12:34:23.173+00:00","320-26-128","2026-09-21",10,{"510k":210,"classification":211,"enforcement":212,"event":213,"event_backfill":214,"pma":215,"warning_letter":216},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]